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Over that last few decades there has been an increase in the creation of new 
medicinal agents to treat various ophthalmic diseases, from small molecule drugs to 
highly targeted biologics.  While these advances in drug discovery have enabled a new 
wave of therapies, many problems regarding their accurate, reproducible and safe 
administration still remain.  The standard vehicle for topical ocular drug delivery is the 
eye drop, and despite its popularity, there are some significant limitations to their use.  It 
is estimated that in many cases less than 5% of the active reaches the target tissues.  
While the remainder of the dose is either spilled out onto surrounding tissue or it is 
rapidly drained through the lacrimal ducts where it can be absorbed into the systemic 
circulation.  Current drug delivery technologies have focused on improving 
bioavailability and patient compliance, and it is expected that further improvements can 
be made in these areas by incorporating the use of precision drug loaded aerosol vortices.  
Within the framework of this dissertation, two main aspects of a novel ophthalmic 
aerosol drug delivery device were investigated; the mechanical features that dictate the 
dose delivery, and the formulation aspects that control the characteristics of the aerosols 
that are being delivered.  In early studies, investigations into the mechanism of the dose 
deposition were explored in order to gain knowledge into predicting the performance and 
 viii
to tune the delivery of a wide range of therapeutic concentrations.  In later studies, after 
the device and dosing characteristics where established, studies were conducted on 
different formulation strategies in order to incorporate active pharmaceutical ingredients 
that would otherwise have unfavorable physicochemical characteristics for incorporation 
into an aqueous based system.  These studies included the use of solubilizing agents and 
their effect on the characteristics of the aerosol generated from the device, as well as a 
novel particle engineering technology that could be utilized to incorporate the use of 
nanoparticles or colloidal particulates into the device or for other uses.  The use of these 
formulation techniques thereby increases scope of therapeutic agents that can be 
incorporated for use in the device, further improving its therapeutic potential.   
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SECTION 1: INTRODUCTION AND BACKROUD 
 
Chapter 1.    Modern Drug Delivery Devices and Formulation Strategies 
for Optimizing Topical Ocular Drug Delivery 
 
INTRODUCTION 
The role of pharmaceutical scientists, engineers and physicians in designing new 
ocular drug delivery systems as whole, is to improve the safety, tolerability and 
convenience for patients in hopes to achieve superior therapeutic outcomes and improve 
quality of life.  Over the last few decades pharmaceutical scientists have made great 
advances in solving some of the major problems associated with delivering medicine to 
the desired ocular tissues.  However, many of these problems still remain due to the 
complex anatomical barriers present in the ocular system.  The internal components of 
the eye are largely protected from the bloodstream by the blood-retina barrier and the 
blood-aqueous barrier.  While a select few drugs can pass through these barriers a 
majority cannot.  Often times, extraordinarily high blood levels, sometimes toxic levels, 
must be achieved in order to get the drug to partition into the tissues of the eye.  It is for 
these reasons the eye is rarely treated via the oral/systemic route.  Delivering medications 
topically to the front of the eye, while better suited than the systemic route, still has major 
barriers.  The major drug delivery barrier for topical administration is the cornea.  More 
specifically, the corneal epithelial layer represents the largest permeation barrier to entry 
into the eye, and is the rate limiting barrier to most hydrophilic drugs (1). 
An overwhelming majority of prescribed medications for treating front of the eye 
diseases are dispensed as solutions in standard multi-use eye-droppers.  Eye drops have 
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been used in treating the eyes for over 100 years and have major advantages in terms of 
expense, ease of manufacturing and general patient acceptance.  Despite their prevalence, 
eye drops have some major limitations and risks associated with their use, especially 
when used for a prolonged period of time or in vulnerable patient populations such as 
pediatrics or geriatrics (2-4). 
 
LIMITATIONS OF THE EYE DROP: 
Formulation aspects: 
Topical instillation of liquids into the eye requires that the physiological features 
of the eye are not severely disrupted.  The eye is highly regulated in terms of pH, 
osmolarity, lipid content, ionic strength, protective mucins etc.  When adding a 
substantial volume into the eye, the tear film is entirely disrupted and diluted with the 
instilled vehicle.  Therefore eye drop formulations must be sterilized, stable and 
osmotically balanced (171 -1711 mOsm/kg).  But because some drugs need to be 
formulated at high concentrations that would normally exceed the isotonic levels, it is 
more important to establish the sterility and purity before adjusting tonicity.  Also, the pH 
of eye-drops must be within range of 2 - 11.5 as to not damage or burn the surface of the 
eye and elicit a foreign body response and thus increase lacrimation and clearance (5).  In 
order to avoid this response, promote retention and maximize absorption, the preparation 
must be formulated between pH 7.0 and 7.7.  In addition the buffering capacity of the 
system must be quite low as to not overtake the endogenous restoration of the tear film, 
which in many cases in unavoidable.  Unfortunately, many of the topical ophthalmic 
agents are alkaloids, such as pilocarpine, have been found to be chemically unstable in 
alkaline solutions so they must be formulated at slightly lower pH of between pH 4 - 5 
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(6).  They must also be formulated with a lower buffer capacity as to not overwhelm the 
natural buffering system in the eye.  Furthermore, the tear film contains many different 
enzymes, some of which could degrade labile drugs from within the tear film.  Finally, 
eye-drop solutions must be sterilized and manufactured under cGMP conditions and 
because they are intended as multi-use aqueous based systems, the formulation must 
contain preservatives to prevent microbial growth or be packaged into disposable single 
use blisters.  And many of these preservatives have been shown to have corneal toxicity 
with prolonged use (7-10). 
 
Dropper Bottle Aspects:  
The eye dropper bottle itself, contributes to the large amount of error associated 
with eye drop administration.  Various manufacturers have designed different bottles 
made of different types of plastic with different nozzle geometries and performance.  
Different plastics provide more or less rigidity and require different amounts of pressure 
to dispense a drop.  In addition, the pressure required to generate drops is also dependent 
on the nozzle diameter.  Smaller diameter nozzles require more force to produce drops 
and have a slower rate of production, while large nozzles require less force and can create 
droplets rapidly with ease (11, 12).  All of these factors play a role in drop size/weight 
uniformity.  The physicochemical characteristics of the formulation and how they interact 
with specific nozzles also plays a role.  The principle behind Tate’s Law is that the 
surface tension of the formulation and the nozzle diameter both play a key role in the 
mass/diameter of droplets produced.  However, in a real word settings patient factors 
often come into play.  Sklubalova and coworkers have extensively investigated several 
other factors that contribute to the dose variability of eye drops.  They found that the 
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dispensing angle is also a major contributor to the size of the drops produced.  Other 
factors they mentioned were: temperature, surface tension of the formulation, specifically 
related to benzalkonium chloride concentration, and rate at which the drops were 
dispensed.  In one tip design they measured drops to be 60% less than what the 
theoretical maximum weights predicted by Tate’s Law would be, indicating the 
complexity of the effects of nozzle design and its interaction with different formulation 
characteristic (13, 14) .  In other studies done German et al. with the Minums® dropper, 
they found very large variability in dispensing doses with the same nozzle.  Because 
these nozzles are manufactured by injection molding, the authors suspect there was very 
little deviation in geometry and the variability was associated with the inherent nozzle 
design and the different interactions between the plastic and the formulation (15).  All of 
these studies highlight the importance of co-developing a formulation side by side with 
the intended dropper to help avoid problems downstream.  
 
PHYSIOLOGICAL LIMITATIONS: 
The stable human tear film contains approximately 7 µL of fluid and the pre-
corneal cul-de-sac can transiently contain up to 30 µL before blinking.  The problem is 
that the volume of typical eye drops ranges between 50 – 75 µL (16).  Upon instillation, a 
large portion the liquid can spill out of the precorneal area onto the surrounding tissue or 
can be rapidly drained through the puncta and down through the nasolacrimal ducts.  
From there the drug can be absorbed into the systemic circulation and metabolized or 
excreted.  Beyond the over-flow, afferent nerves innervated into the ocular surface are 
capable of detecting transient changes in environmental conditions, such as: pH, carbonic 
acid levels and fluid levels.  Upon activation, these nerves send signals to the efferent 
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parasympathetic nervous system which stimulates the lacrimal gland to produce tears 
(17).  This is known as reflex tearing and depending on the strength of the signal, it can 
cause a disproportionate amount of drainage in attempts to clear the surface and re-
establish homeostasis.  Ultimately, this results in a very low residence time for drugs 
instilled into the precorneal film.  It has been estimated that the instilled drug is cleared 
from the front of the eye in less than 5 minutes (18).  Because of this clearance rate, in 
order to increase the dose, an additional drop would need to be instilled outside of the 
five minute window because any additional fluid added would not alter the concentration 
at the surface, it would only replace the fluid residing with the same concentration.  This 
subsequent drop time limitation has been shown to be a major source of error in the 
scaling of doses in terms of bioavailability and even efficacy in some cases.  
Furthermore, this dosing problem becomes more troublesome when incorporating a 
second eye drop medication.  Because the initial dose causes an increase in tear 
production/drainage, the second instilled medication will have a diminished residence 
time.  In addition, this second medication further dilutes the initially instilled eye drop, 
ultimately causing both to be less effective (19).  The evidence provided by Chrai et al. 
strongly supports the use of combination drug products (i.e. incorporating two drugs in a 
single solution) in cases where multiple drugs are necessary for treatment. 
 
Anatomical Barriers: 
Delivering medications from the front of the eye into the interior structures 
requires overcoming several barriers, both from a physicochemical and structural 
perspective.  The first barrier protecting the front of the eye is the tear film.  The tear film 
is comprised of a lipid layer floating on top of an aqueous layer.  This lipid layer serves 
 6
to both lubricate the surface of the eye between blinks but its main role is to limit or 
reduce evaporation of the aqueous layer.  The next layer is the aqueous layer which 
contains a multitude of water soluble entities such as ions, proteins/enzymes and mucins.  
The aqueous layer serves many different roles in maintaining the health of the corneal 
cells, including replenishing nutrients and maintaining hydration.  The aqueous layer also 
presents a barrier to the solubilization capacity for poorly water soluble drugs.  Insoluble 
drugs delivered as suspensions must first pass into solution before they can be absorbed 
through the cornea, and often times these molecules cannot establish a high enough 
concentration to be absorbed sufficiently because of their low aqueous phase solubility. 
While there are several routes of entry into the anterior of the eye, they can 
basically be broken down in two main routes: corneal and non-corneal.  Entry through the 
cornea represents a unique challenge in comparison other biological membranes or 
structures, in that it is comprised of three alternating multi-phasic layers (i.e. lipophilic-
hydrophilic-lipophilic).  In addition, the apical cells are connected via tight junction 
structures (zonula occludens) which often severely limit paracellular transport, therefore 
a large portion of drug transport processes rely on transcellular mechanisms.  The 
outermost layer, the epithelium, is lipophilic and allows for more oily compounds to 
penetrate.  The middle layer of the cornea is the stroma.  It is approximately 450 µm thick 
and comprised of multiple hydrophilic plates of collagen fibrils, and contributes to 90% 
of the corneal thickness (20).  Finally, the innermost layer, the endothelium, is lipophilic 
but it is also formed in conjunction with the Buchman’s membrane.  This serves as the 
last physical barrier before entering in the aqueous humor.  Because of this multi-phasic 
nature, certain molecules will have advantages over others and a balance between 
lipophilicity and hydrophilicity must be in order so that the molecule can transition 
through the layers with the least resistance.  Barring the occurrence of transporters and 
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permeation enhancers, this permeation rate is almost entirely based on the 
physicochemical properties of the drug molecule itself. 
Non-corneal entry is bit less direct in that it includes direct penetration through 
the conjunctiva and sclera and into the anterior uvea, where it can diffuse throughout the 
other tissues.  The apical layer of the conjunctiva is also more permeable to hydrophilic 
molecules as well as some peptides or macromolecules, and due to looser junctions it can 
facilitate more paracellular transport.  The non-corneal surface area is roughly 20 times 
larger than that of the cornea and can allow for the transport of drug molecules that would 
normally not penetrate the cornea (21).  However, this absorption is also still severely 
limited because it is in concurrent competition with the ocular and conjunctival 
vasculature for loss via systemic circulation (22).  
 
PATIENT COMPLIANCE/ADHERENCE:  
Social and Psychological Barriers: 
Patient compliance is a well known contributor to the success or failure of an 
ophthalmic drug therapy.  The patient compliance aspect is especially magnified in cases 
where chronic or lifelong therapy is necessary for success.  After analyzing several large 
datasets from pharmacy claims, Friedman et al. proposed the actual adherence to 
glaucoma treatment is below 50% (23).  Of the contributors to patient 
compliance/adherence, the main contributors fall into two main categories: voluntary 
non-compliance and involuntary noncompliance.  In a study conducted by Konstas et al., 
44% of patients were not compliant with their glaucoma medication to a point where it 
became clinically significant.  Of the 44%, 29% were voluntary and 15% were 
involuntary non-compliance (24). 
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Voluntary non-compliance in centered around the patient’s attitude towards a 
therapy or the social circumstances in which the patient chooses to not take the 
medication they already acquired.  It also includes circumstantial situations, including 
lifestyle matters that inhibit their usage.  Some of the most often cited reasons for 
voluntary patient noncompliance are: forgetfulness due to complicated dosing regimens, 
situational events which disrupt scheduling, costs and health provider convenience, low 
health literacy, and lack of perceived disease severity (25).  While it was cited that 
simplifying dosing regimens could improve outcomes, from a pharmaceutical 
development perspective, outside of significantly altering dose potency and duration, 
very little can be done to alleviate the behavioral problems (26).  It is important to stress 
the significance of patient education from healthcare professionals in order to equip 
patients with the correct mindset while undergoing therapy.  Improving communication 
between patient and prescriber is a well established means to improve rates of adherence 
and with technical advances in therapy the two can work synergistically for optimize 
patient outcomes (24). 
The other source of noncompliance, involuntary compliance also known as 
dyscompliance, relates specifically to patients who willfully comply with dosing 
regimens however they cannot practically administer the medications correctly.  In these 
situations, very little can be done from an educational perspective; however vigilance in 
assessing and monitoring proper patient use of devices to ensure they are competent in 
their use.  A majority of the most highly cited sources of error with administration are 
related to the use of eye drops in particular.  Some of the most common difficulties are 
associated with proper squeezing the dropper bottle, especially in geriatric populations.  
Often times, in these cases more than one drop can be dispensed.  In addition, patients 
also reported difficulty seeing the dropper bottle tip and therefore had trouble aligning 
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and allowing the droplet to fall into the eye, and in some cases touching the dropper tip to 
the eye (27-29).  It is in these arenas pharmaceutical scientists and engineers can develop 
novel devices and dosage forms in order to make accurate dosing more convenient, 
especially for those with physical limitations. 
 
STRATEGIES FOR IMPROVING TOPICAL OCULAR DRUG DELIVERY 
A majority of the strategies used to improve ocular bioavailability are based on 
increasing the residence time in the precorneal film, increasing the drug concentration or 
the incorporation of permeation enhancers.  However, in some cases it may not be 
feasible to increase to the concentration or include permeation enhancers due to 
toxicological effects (30).  Therefore, the safest approach is to increase the tear film 
residence time.  One way to increase residence time is to increase the viscosity of the 
instilled liquid, by incorporating hydrophilic polymers or other viscous liquids (31).  
Improving residence time can also be achieved by using microparticulates and by 
incorporating some bioadhesive polymers to entangle the mucin layer of the corneal 
epithelium.  The downside of these techniques is that many times these 
solutions/suspensions can cause blurring of the vision and can be irritating to the patient.  
In addition, special care must be taken to ensure particulates are smaller than 10 µm in 
order to eliminate possible corneal abrasions.  The other strategy is to reduce tear 
production, thus reducing drainage and elimination of the drug from the ocular surface.  
While it has been established that many different mechanisms including, temperature, 
pH, and tonicity can irritate the ocular surface and instigate tearing, the eye is also 
sensitive to the volume of the liquid in the pre-corneal space.  
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Instilled Volume and Retention in the Tear Film 
In a landmark paper, Chrai et al. investigated tear film turnover rates in rabbits as 
well as the effect that different instilled volumes have on the drainage rates (16).  In order 
to investigate tear film residence, they conducted non-sampling lacrimal fluid turnover 
tests using radioactive technetium colloids.  They instilled the radioactive technetium 
solution in different volumes and immediately began collecting data.  As can be seen in 
Figure 1.1, the fraction of the remaining tracer for 50 µL instillation volume falls 
considerably fast within the first few minutes, while the 5 µL drops have a much more 
gradual decline.  At 25 minutes 50% of the 5 µL dose still remains, while only about 10% 
remains for the 50 µL drop (16).  The authors suggest that the explanation for the 
disparity is that two competing drainage mechanisms are occurring simultaneously, rapid 
drainage of the instilled volume and natural basal tear turnover.  So in the case of the 
larger volume, the rapid decline is due to drainage and the second phase or plateau is due 
to the tear turnover.  In the case of the small volume, the initial drainage is drastically 
reduced and the predominating clearance is done by the basal tear turnover.  This idea is 
further supported because of the intermediate clearance rates are also observed at with 
intermediate instillation volumes. 
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Figure 1.1.  Decreasing the dosing volume of instilled eye drops showed large 
improvements in tear film retention over time.  Adapted from Chrai et al, 
1973 
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Drop Volume and Bioavailability 
 
As follows from the improved retention time, Chrai et al. also demonstrated that 
this small volume effect also translates to improved ocular bioavailability by measuring 
in-vivo activity.  They measured the pupil miosis from a fixed dose of 0.136 mg of 
Pilocarpine Nitrate administered at different concentrations and volumes.  They 
compared instilled volumes of 5, 10, 25, 50 and 75 µL and they found that the 5 µL drops 
had double the peak effect compared to the 75 µL, and the AUC was ~4 fold that of the 
75 µL. 
It has long been known that one could improve the retention in the front of the eye 
by increasing the viscosity of the vehicle as in ointments and gels, but this was of the first 
times it was demonstrated that by simply reducing the instilled volume it would improve 
the residence time without altering the structure of the drug or adding permeation 
enhancers to improve permeability.  Therefore, these findings were very important 
because they offered a new simple way to improve efficacy without increasing exposure 
or dramatically altering the formulation. 
 
Bioavailability: Competing Drug Permeability vs Drainage Rate 
Many years later, Keister et al. mathematically described the relationship between 
the time dependent integral of drug tear film concentration and flux across the corneal 
membrane.  And by using the known first order decay for the tear film, it was shown that 
the maximal tear film concentration over time could be achieved by instilling a virtual 
“zero” volume drop (32).  Figure 1.2 shows that when a drug has a lower permeability 
and a fast drainage rate, there is a zero-drop effect.  The zero-drop effect is the theoretical 
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maximum bioavailability that can be achieved due to minimizing the instilled volume.  
As the instilled volume approaches zero (µLs), the effects of induced drainage and 
clearance are minimized.  Furthermore, the degree at which the zero-volume effect occurs 
is highly related to the physico-chemical properties of the drug, and the interactions of 
the drug with local physiology.  In cases where the drug is highly permeable and drainage 
from surface is low, the volume of the instilled drop does not have an effect on the 
absorption.  This is the theoretical best case scenario, however it is practically very rarely 
observed (without nasolacrimal occlusion, which is discussed elsewhere (33)).  The most 
common case would be where the drug has intermediate permeability and an intermediate 
or variable drainage rate.  Finally, at this point in time,  it is has been well established that 
instilled volumes larger than the stable tear film instigate tear production rate and the 
transient dilution in the tear film by nearly doubles its normal rate (34, 35). 
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Figure 1.2.  Theoretical relationship between ocular bioavailability and instilled drop 
volume when controlling for dose.  The drug drainage rate and permeability 
are a major influence in the ocular bioavailability.  Adapted from Keister et 
al.,1991 
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Environmental and Pharmacological Effects on Tear Film Retention 
The baseline level of tear production is approximately 0.5 µL- 3 µL/minute, this 
means that typical tear turnover should be between 5 and 30 minutes (36).  However 
because of complexity in the physiological conditions and variability between patients 
the effects of tear production can be quite large.  Physical/chemical irritation and/or 
emotional factors can cause reflex tear production to increase from 3 to 400 µL (34, 37).  
In addition, transient changes in temperature or relative humidity can also affect basal 
tear production/turnover.  All of these various factors, both predictable and not, can affect 
the clearance of the drug from the surface of eye.  For example, the topical administration 
of decongestants causes vasoconstriction of the capillaries in the eyes in order to reduce 
redness.  But when this vasoconstriction occurs in the cavernous body of cannicula in the 
nasolacrimal ducts, it causes a reduction in extracellular tissue volume which then causes 
the opening of the duct way lumen.  In this scenario, the addition of the drug molecule 
itself pharmacologically exacerbates or alters the drainage from the precorneal film (38, 
39).  Conversely, some ophthalmic drugs that are irritating can produce a foreign body 
response which can simultaneously increase tear production and cause constriction of the 
drainage ducts causing highly variable changes in precorneal film retention.  Therefore, 
due to the dynamic and many times unpredictable changes in basal tear drainage or 
clearance it would be pragmatic to reduce drug instillation volume to improve 
bioavailability and reduce variability whenever possible (35, 40, 41).   
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PREVIOUS INVESTIGATIONS INTO UTILIZING SMALL DROP VOLUMES OR SPRAYS: 
Halberg et al. conducted early trials in humans for the use of topical ophthalmic 
sprays as an alternative means to administer glaucoma medicine to the eye.  Patients were 
given 1 drop of a 1, 2 or 4% pilocarpine in one eye and the same concentration of the 
spray in the other eye.  The drop in intra-ocular pressure was comparable to between the 
spray and drop at each time point, and after 120 minutes both eyes saw similar declines in 
activity.  They also conducted a similar study over the course of the 3 months and the 
sprays were shown to control the intraocular pressure as well as the drops (42).  
Since then several groups have investigated the use of topical ocular sprays for 
several different applications.  Akman et al. showed equal pupil dilation between a 1% 
spray of tropicamide and an eye drops, but with less discomfort than the drops (43).  
Several others researchers have investigated sprays for use as cycloplegics and mydriatics 
for pediatric applications because of the routine nature of eye exams and the potential for 
decrease systemic effects (44-49).  In addition, it has been well established that the 
medicine instilled in the eyes can rapidly absorb into the systemic circulation and cause 
systemic effects.  However, recently Alpay et al. reported two case studies where excess 
eye drops spilled out of the eyes and on the eye lids and face, where they cause extreme 
discoloration.  There was clear evidence of percutaneous absorption indicated by 
localized pale regions where vasoconstriction occurred (Figure 1.3, below).  Neonates are 
especially vulnerable to the systemic effects of the commonly used mydriatic drugs due 
to having a decreased or immature metabolism and small body weight but at this age their 
epidermis is not quite fully developed (50).  Special care must be taken to ensure excess 
drug is wiped away from the skin to limit the risks for systemic exposure.  Furthermore, 
researchers suggest minimizing drop volume and performing nasolacrimal occlusion to 
further reduce any risks (49, 51).  
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Figure 1.3.  Skin paleness around the eyes due to overflow and vasoconstriction from 
mydriatic eye drops. (Alpay et al., 2010) 
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CURRENT TECHNOLOGIES FOR DELIVERING SMALL VOLUMES TO THE EYE 
Small Volume Dosage Forms and Formulation Strategies: 
Delivering small volumes into the ocular space has shown to be a tedious and 
technical task, especially when dealing with low viscosity liquids.  Standard dropper 
bottles are not capable of delivering micro drops because they are limited by the 
geometry of the nozzle as well as the surface tension and rheology of the formulation 
(52).  In addition there is a practical limit in the reduction in droplet size from 
formulation approaches and in many cases it may not be optimal to alter the formulation 
in hopes to reduce the droplet size because of some other less desirable effect on the 
tolerance of the formulation.  For the purposes of this manuscript, non-liquids (i.e. semi-
solids) will be considered as they do not contribute excess liquids into the ocular cavity.  
They may however contribute the foreign body response on a case by case basis. 
 
Ophthalmic Ointments: 
One popular dosage for topical delivery is the ophthalmic ointment.  Ointments 
are effective for two main reasons.  They are able to drastically improve the residence 
time in the precorneal space and they are generally well tolerated.  In some cases they 
may even be soothing to topical inflammation.  While topical ophthalmic ointments are 
beneficial for improving residence which leads to improved bioavailability, they have a 
few drawbacks to their regular use.  Ointments are well known to cause blurred vision, 
which can lead to poor patient compliance.  Furthermore, because of their semisolid 
nature are prone to mishandling and dosing inaccuracies (53, 54).  Finally, due to the 
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inherent increased contact time, the patient will also have increased exposure to 
preservatives, many of which have been shown to have toxicities.  
 
Semifluorinated Alkanes (SFAs): 
Beyond using aqueous based vehicles, researchers have been investigating a new 
class of compounds with properties that are quite favorable for ophthalmic use, 
Semifluorinated alkanes(SFAs).  Semifluorinated alkanes are molecules that have a 
perfluorocarbon chain attached to a hydrocarbon chain.  Ophthalmologists have 
successfully used SFAs as tamponade agents during complex retinal surgeries, and they 
have been shown to be chemically and physiologically inert and have very low surface 
tensions (55). When formulating aqueous based vehicles there is a practical limit the 
reduction in the size of the droplet produced.  This is due to the limitation of the 
effectiveness of surfactants and other excipients in further reducing the surface tension.  
When formulating with SFAs, not only is there in inherent reduction in surface tension 
allowing for smaller droplet formation from the SFA, they are also quite good solvents 
for a large number of drug substances(56).  In addition, they have comparable refractive 
index to that of water, so vision blurring would be minimized.  Furthermore, Dutescu et 
al. also found that SFAs were adequate solvents for cyclosporine and were superior to the 
brand product, Restasis® (ophthalmic emulsion) in promoting in-vitro permeability of 
cyclosporine into the anterior chamber.  Based on predictions done by Wiederholt et al., 
the concentrations achieved could be therapeutically relevant for treating internal 
inflammation(57).  While in the case of dry eye syndrome, Novaliq®, a company based 
off of SFA technology currently has several products currently in development and in 
various stages of clinical trials.  
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OPHTHALMIC INSERTS- ERODIBLE/DISSOLVING 
 
Novel Ocular Delivery System (NODS): 
A more recent advance in the area of improving ophthalmic retention and 
bioavailability is the use of insertable drug loaded water soluble films.  The NODS films 
were developed by Chauvin Pharmaceuticals Ltd., and overcome some of the problems 
associated with previous ocular inserts such as the Ocursert®.  Earlier inserts suffered 
from problems of local irritation and they would commonly be ejected from palpebral 
fissure.  The NODS units are different in that they are very small and flat so they can 
easily be inserted into the conjunctival sac with the applicator.  Once inserted the water 
soluble polymers begin to hydrate/dissolve and release the drug dispersion.  NODS have 
been demonstrated to be as effective in delivering tropicamide to that of drops but had a 
much longer duration.  NODS have also been evaluated for use with chloramphenicol and 
pilocarpine.  They offer a particular benefit for patients who have difficulty administering 
eye drops and can be an effective delivery system for immediate and controlled release 
(58).    
 
Lyophilates: 
Similar to the NODS system, Steinfeld and Lux et al. developed the use of a drug 
loaded solid lyophilate which is designed to be inserted into the conjunctival sac of the 
lower eye lid (Figure 1.4).  The lyophilate can be made with hydroxypropyl 
methylcellose and the active ingredient or they can be made with neat drug.  All 
solids/powders are intended to dissolve into the pre-existing tears and form high 
concentration gradient.  This dosage form is administered to the prebulbar fissure via a 
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matchstick sized applicator.  Upon blinking the powder disperse into the tear film where 
they are dissolved at very high concentrations.  In a pilot study using fluorescein, 
scientists were able to see a 4 fold increase precorneal film retention and showed an 
increase in corneal permeability as assessed by the increased anterior chamber 
concentration compared to the eye drops (34, 59).  In addition to lyophilates others have 
investigated the use of dry powders for topical administration to the eye.  Hardarson et al. 
demonstrated that timolol dry powder formulations were well tolerated in the rabbit eyes, 
and showed that this dosage form/delivery method could provide a simplified means to 
avoid the use of toxic preservatives found in aqueous based eye drops(60).  
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Figure 1.4.  Patient applying solid lyophilate to the conjunctival sac with an applicator 
(Lux, 2014) 
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Nanowafers 
Researchers at Baylor College of Medicine have been investigating the use of 
these customized microfabricated nanowafers for use in topical ophthalmic 
administration.  The fabrication of these wafers begins with using e-beam lithography to 
generate 500 nm wells into the surface of a silicon wafer to form a master template.  
From there, a poly (dimethylsiloxan) positive imprint is cast.  This imprint is then used to 
create polyvinyl acetate mold with approximately 500 nm wide divots.  Finally a polymer 
drug solution is then loaded into the wells.  In one experiment, doxycycline wafers were 
applied topically to anesthetized mice.  Researchers were able to detect high levels of the 
drug in the tear film after 2 hrs and detected its presence in the cornea for up to 24 hrs 
using intravital confocal microscopy (61).  Furthermore, this research group has also 
investigated a large number of peptides and biologics for use in this system.  This 
technology appears to be very promising because they have observed increased 
permeability and increased residence time in the front of the eye, and because it utilizes 
materials that have already been established as safe are commonly used in the eye this 
technology should translate easily into clinical trials (61).  
 
 
NON-ERODIBLE INSERTS: 
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Ocusert ® Alza Corp.,CA, USA 
One of the first modified release dosage forms for use in the eye is the Ocusert® 
Device.  This dosage form is comprised of pilocarpine HCl mixed with alginate gel 
mixture formed into a rod-type geometry and has drug release rate controlling membrane 
surrounding the drug mixture.  The tube like geometry is then connected end to end to 
form a soft white circular ring.  This is used by placing into the inferior cul-de-sac (lower 
eyelid).  This device can be worn continuously throughout the day to alleviate the need 
for applying multiple doses to the eyes.   
 
 
CONTACT LENSES 
 
Vistakon®  Drug loaded contact lenses: 
 Contact lenses have been widely investigated in their role as a drug delivery 
vehicle for few different reasons.  For one, they have been shown to be well tolerated in 
many different patient populations and can be self administered.  Fundamentally, contact 
lenses are a biocompatible hydrogel which is an excellent material to contain and offer 
prolonged release of an active compound.  The use of contact lenses as drug loaded 
carriers solves a couple key problems with ocular drug delivery.  Mainly the use of drug 
loaded contact lenses obviates the need for frequent dosing with eye drops which leads to 
better compliance.  In addition the steady state release of the drug offers a more 
consistent pharmacokinetic profile and reduces errors associated with improper patient 
dosing.  Several researchers and a couple companies have investigated their use with 
several different drugs such as: timolol, dexamethasone, and various beta-blockers, 
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antihistamines and antimicrobials for treating front of the eye diseases (62, 63).  There 
are currently no commercially available drug loaded contact lenses on the market, 
however, Vistakon® Pharmaceuticals (a Division of Johnson and Johnson) has 
previously conducted a couple Phase III clinical trials for safety and efficacy for ketotifen 
loaded lenses.  In the safety study, the drug loaded lenses did not show any statistically 
significant differences in irritation or makers for toxicity to that of the blank contact lens 
(64, 65).  Also, non drug loaded approaches have been investigated as well.  In 2014, 
SEED Company Pte Ltd looked into the effects of alginic acid loaded contact lenses for 
the treatment of Dry Eye (66).   
 
 
Intracanalicular Depot 
One type of system that operates very similar to punctal plugs is the 
intracanalicular depot developed by Ocular Therapeutix™, Inc.  This dosage form is 
comprised of proprietary polyethylene glycol (PEG) hydrogel polymer matrix which is 
loaded with drug and inserted into the lacrimal duct.  Upon coming in contact with tear 
fluid, the implant swells and holds itself tightly within the duct.  Over time the devices 
erodes while drug diffuses outwards toward the tear film for a sustained effect.  This 
device offers a couple unique advantages over other punctal type systems.  Firstly, this 
device is composed of a swellable smart polymer which expands to hold the device in 
place as opposed to having an anchor type system used in other technologies.  Also, 
because it is inserted beyond the puncta orifice, it is invisible from a cosmetic 
perspective.  Another unique feature is that because the device can’t be seen from the 
outside, patients can confirm its presence using a special light which illuminates a 
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fluorescent tag from within dosage form.  Finally, a major advantage of this type of 
system is that the dosage form erodes and is washed out through the lacrimal system once 
the dose has been administered.  Other systems require removal from specialized health 
care personnel.  
In a recent clinical study assessing reduction in intraocular pressure, a 90 day 
supply of travoprost supplied by the implant was comparable to timolol drops applied 
twice daily with a blank punctal plug used for masking purposes (67).  In addition to 
glaucoma and ocular hypertension, this device is also being assessed for its potential in 
delivering dexamethasone for treating Dry Eye, Chronic Allergic Conjunctivitis, as well 
as ocular inflammation and pain associated with cataract surgery (68-70).  
 
 
Punctal Plugs 
One type of a drug eluting punctal plug system originally investigated by QLT 
Inc., and now being developed by Mati Therapeutics Inc., The Evolute®, consists of a 
drug loaded core that is encapsulated in either a plunger or L-shaped silicone geometry.  
This specific geometry was designed in order to enhance retention in the puncta after it is 
inserted into the lower puncta with a proprietary tool.  The use of a punctal plug type 
system overcomes many of the limitations of eye drops, and other types of inserts.  This 
system eliminates the need for preservatives and reduces patient compliance and 
adherence effects of eye drops.  Furthermore, this system is not cosmetically noticeable, 
does not interfere with patient vision.  Finally, this plug does not make prolonged contact 
with the corneal epithelia as in the case with contact lenses which thereby reduces risks 
for corneal abrasions or irritation.  In a recent phase II clinical trial with latanoprost, 
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results showed a consistent reduction of intraocular pressure of about 5 mmHg over 12 
week period with a very high ocular retention rate of 92% and very few serious adverse 
events (71, 72).  Some of the drawbacks of this system from a formulation aspect are that 
because of the small geometric size of the system there is a limitation in the maximal 
dose loading available.  This restricts the therapeutic uses to either highly potent 
compounds for prolonged effects or to less potent drugs for a shorter duration.  From a 
patient's perspective, the major drawback is that it requires a doctor's visit for 
administration and in a small number of patients excessive lacrimation was observed.  
Future clinical trials are being planned for use in treating ocular allergies and 
inflammation in addition to a phase III trial for glaucoma with latanoprost (73).  
There are also non-drug loaded punctal inserts designed specifically to obstruct 
tear flow and drainage, such as the Parasol® Punctual Occluder.  These devices can be 
used to treat symptoms of Dry Eye in cases when root cause is where tear production is 
lower than normal.  In addition, there are also specialized occluders which have small 
channels within them to allow for passage of some tear fluid but to overall serve to assist 
in allowing tear film accumulation.  Finally, plugs can be used in conjunction with other 
topically instilled solutions in some cases.  Studies have also shown that use of topical 
cyclosporine eye drops can have an additive benefit in treating dry eye above what either 
the drops or the plugs have been shown to do alone (74).  
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DRUG DELIVERY DEVICES/COMBINATION PRODUCTS: 
 
Compliance/Coordination Devices: 
Over the last several years there have been a large number of devices to assist in 
the instillation of the eye drops.  These devices for the most part assist patients in 
aligning the dropper tip over the eye and/or in the depression of the bottle for patients 
who have difficulty squeezing the bottle to produce a single drop.  One example, the Xal-
Ease™ (Pfizer Ophthalmics, New York, York), allows the patient to the load a 
prescription eye-drop bottle of Xalatan ® (0.005% latanoprost) into the device and it is 
equipped with an attachment to assist in removing the eye dropper lid to reduce possible 
contamination.  The patient can then align the eyepiece of the device around the ocular 
orbital and administer the medication from a horizontal position by squeezing an actuator 
trigger as depicted in Figure 1.5.   
In a previous clinical trial, patients much preferred this device over standard drops 
and the outcomes of the results showed no clinical significant difference between the 
dropper bottle and the device  (75, 76).  While this device does not significantly reduce 
the droplet size that is instilled per say, it does however, help to ensure that patients are 
able to administer the proper the number of drops and deposit them properly (77).  One of 
the downsides to the Xal-Ease device is that it is specially designed to only hold the 
Xalatan dropper bottles.  There are however, other devices aimed at being more universal 
such as the Auto-drop® and the Easy Drop®.  And for use in patients with limited 
dexterity or with rheumatoid arthritis there have been others introduced such as the 
Opticare Eye Drop Dispenser® and Opticare Ortho® shown in Figure 1.6.  Another 
device that works in a slightly different method than the previous administration aids and 
is available over-the-counter, is the SimplyTouch® eye-drop applicator.  This device 
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allows the patient to place a drop from their existing bottle into small divot or reservoir at 
the end of a soft plastic applicator Figure 1.7.  The droplet is held in place by surface 
tension and the patient can then touch the droplet to the eye and it is quickly wicked 
away.  This device appears to overcome many of the technical difficulties with 
administration and would also help to reduce wasting from over squeezing dropper 
bottles, however there may still be some concerns with cleanliness with re-use as well as 
possible damage done to the surface of the eye if incorrect contact is made.  Furthermore, 
because the applicator relies on a fixed volume for administration variances in 
formulation composition can possibly fill the reservoir to different levels depending on 
surface tension, viscosity density etc.  For simple formulations, this applicator appears to 
be promising. 
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Figure 1.5.  Xal-Ease® containing a bottle of Xalatan® be actuated into a test tube for 
analysis (Semes, 2007) 
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Figure 1.6.  Versatile eye drop dispensers for patients with limited dexterity.  Opticare 
Ortho ® (left) and Opticare ® , The Eye Drop Dispenser ® (right). (Get 
Permission from Cameron Graham, Ltd.) (Programs to optimize adherence 
in glaucoma. (Kowing et al, 2010) 
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Figure 1.7.  SimplyTouch® Eye Drop Applicator.  The prescription side serves as a stage 
to hold the eye drop, while the other side has a reservoir to hold large non-
medicated drops. 
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METERED/MICRO-DROPPER DEVICES 
 
μ-Drop™  
The mu-drop technology is a cartridge or blister type system that allows patients 
to load a blister containing a certain number of doses into a dispensing unit.  This unit 
contains an internal needle which punctures the blister allowing the internal drug solution 
to pass down a narrow channel.  The inventors of this technology found that by applying 
a set amount of force onto the blister via the actuator, they can produce very reproducible 
droplet volumes.  Furthermore, they found a direct correlation between needle/channel 
diameter and droplet size.  By utilizing such a small channels, the authors claim this 
device is capable of producing droplets in the 2 -25 µL range (78).   
In a recent proof of concept clinical trial involving 30 healthy volunteers, the 
effect of droplet size on pupil dilation was assessed using the topical mydriatic, 
tropicamide.  In addition to measuring pupil size ten times over a 2 hr period, the patients 
filled out a questionnaire to assess any adverse effects.  One group received a micro-drop 
of 2.4 µL in both eyes while the other group received a standard drop, 38 µL.  In both 
cases a 0.5% tropicamide solution.  After a 7 day wash out the other drop was 
administered and the same measurements and questionnaire were used (79).  
Scientists found that non-inferior mydriasis could be achieved using the micro-
drop, which had 15 times less volume than the standard drop, and all of the patients 
experience pupil dilation adequate for general fundoscopy.  Furthermore, according to the 
questionnaire, patients experienced few adverse effects and a large reduction in 
complaints of irritation/discomfort in the micro-drops vs. the standard drops (79).    
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Eyeinstill™ Device (MEDInstill™, CT, USA) 
 
MedInstill Technologies has created an Intact ™ one-way visco-elastic valve that 
allows fluids to be dispensed while serving as a non-contamination barrier.  The concept 
of the valve is based around how the valves in the arteries of the cardiovascular system 
operate.  The inventors claim that the valve allows for dispensing accurate, reproducible 
volumes of liquid formulations as low as 20 µL, all while preventing outside 
contaminants from entering.  This technology could have major benefits in formulating 
multi-use drops without preservatives, especially for those which have been shown to 
have toxicities (7-9).    
 
Novelia®- Sterile multi-dose dropper (Numera, France) 
The only currently marketed preservative free multi-dose system commercialized 
in the US is the Novelia® device.  This device prevents the ingress of contaminants using 
the PureFlow™ technology.  The one-way valve can fit onto many different types of 
bottles and is capable of dispensing suspensions and high viscosity liquids.   
 
IONTOPHORETIC DEVICES/SYSTEMS 
 
Recently, several new iontophoresis technologies have been coming down the 
development pipeline.  All of these technologies have the same basic operational concept 
in that, and electric field is used to migrate selectively ionized (or polar) molecules across 
key membranes, including the cornea, sclera and choroid, and even into the retina (80).  
While the dosing will require a doctor's visit, this technology has a major advantage over 
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injectable or implantable dosage forms, which have an increased risk of hemorrhage, 
retinal detachment or infection.  This non-invasive technique has been used with large 
number of corticosteroids and antibiotics, as well as macromolecules and dendrimers or 
small nanoparticles (81-84).  The actives/particles can be loaded in a solution or gel 
which applied to dosing chamber which makes contact with the ocular surface via 
different geometries depending on the application and device.  
 
Polymer/Hydrogel Based Systems 
 The OcuPhor™ hydrogel (Iomed Inc., Salt Lake City, USA) is made of a 
polyacetal sponge which is loaded with a drug formulation and an electrode which can be 
placed in the inferior cul-de-sac adjacent to the sclera, and is then controlled by an 
external dosing device controller.  Another similar device is the Visulex ™ (Aciont Inc., 
Salt Lake City, UT, USA).  This device has a couple unique features that differentiate it 
from others.  It has an optimized scleral shaped geometry to avoid exposing the 
surrounding tissue to the drug, thus preventing loss and systemic effects, and an in-situ 
drug depot mechanism.  The Visulex ™ device imparts electrical energy onto the drug 
ions and the counter-ions while in solution, causing them to both penetrate into the target 
tissue, where they are joined together and form a precipitate.  This precipitate will have 
reduced permeability and thus can act as a reservoir for a sustained effect (80).  
Furthermore, proof of concept work was done in a rabbit model demonstrating that the 
depot effect can also occur in the back of the eye with a small molecule and also with 
macromolecules (82, 85). 
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The Eyegate® II System (Waltham, MA, USA) 
The Eyegate® II System uses a ring shaped silicone eyepiece that is designed to 
go around the cornea and only make contact with the sclera for trans-scleral delivery, and 
is capable of delivering medications to both the anterior and posterior segments of the eye 
(Figure 1.8).  When comparing the amount of drug absorbed from frequent eye-drop 
instillation compared to iontophoresis using the Eyegate® II,  a single transcorneal 
iontophoretic session of 1 minute @ 1 mA showed a 30 fold levels of dexamethasone 
phosphate in the cornea(81, 86).  The flagship drug(lead clinical compound) for use in 
this combination product is EGP-437(dexamethasone phosphate) was granted orphan 
status in January 2009 for use in corneal graft rejection and has since been evaluated in 
various clinical trials for different indications including: anterior uveitis, dry eye 
syndrome and for use in cataract surgery with intraocular lens replacement (87, 88).  
Furthermore, early phase clinical trials are underway for its use in treating macular edema 
(89).   
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Figure 1.8.  EyeGate® II Delivery System: A Transcleral Annular Iontophoresis Device. 
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Despite being dramatically less invasive than injectable or implantable dosage 
forms and offering much higher absorption and retention than most topical systems, the 
major limitation is that these systems require inconvenient doctor's office visits and the 6 
month to 1 year sustained effect from implantable or injectable system is superior at this 
point.  Future efforts are being pushed into developing sustained release dosage forms to 
be delivered by this method such as with the Visulex system™.  This system draws the 
drug molecule and the counter ion into the tissue where it can precipitate and form a 
depot.  While this technology is promising and exciting, this technology is still in early 
stage clinical trials (90).   
 
 
OPHTHALMIC SPRAYS/MISTING DEVICES: 
 
Versidoser ™ (Mystic Pharmaceuticals, Austin, TX, USA) 
This platform device uses novel unit dose packaging that is incorporated into their 
multi-dose delivery device.  The unit-doses can be formulated preservative-free and when 
used in the device they allow the patient to conveniently administer a 12-15 µL spray to 
the ocular surface.  This device is equipped with a dose counter and ergonomic design to 
assist in patient compliance (91) .  A pilot study published in 2010, investigated the use 
of a Nautilus 1.0 VersiDoser™  was used to administer 30 µL of the investigational drug 
MC-1101 to 11 patients with (dry) age-related macular degeneration, and to 20 normal 
patients aged 50 - 89 years old.  The goal was to investigate MC-1101’s ability to restore 
choroidal blood flow, which helps alleviate the progression of AMD at this stage.  They 
found that the compound was well tolerated in both populations and choroidal blood flow 
 39
and velocity was increased in all patients that received the active compared to vehicle, 
however patients with AMD had a more variable response.  The authors attributed this to 
the difficulty in assessing these parameters in this patient population due to the disruptive 
physiological state, and that further testing would need to be conducted to establish the 
role of MC-1101 in modulating choroidal blood flow (92).  
 
Optimyst™  Nebulizer  
 The Optimyst™ ophthalmic nebulizer is a misting delivery device that 
contains a disposable medication reservoir that is intended to sterile filled.  The solution 
is propelled through an ultrasonic or vibrating mesh actuator to form droplets in the 1 - 10 
µm range, which can be seen in Figure 1.9.  The aerosol generator is able to both, form 
the droplets as well as impart a forward inertia and allow them to propagate towards the 
eye.  To administer the medication, the patient would hold the device in front of the eye 
and depress a button sending stream of droplets outward in plume in the eye. 
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Figure 1.9.  Optimist Ophtalmic Nebulizer Prototype Device emitting a spray plume 
(Collins et at., 2007) 
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In 2007, a clinical study conducted by Collins et al. evaluated the effectiveness of 
a topical mist (6 µL) versus an instilled solution of 30 µL.  They administered a topical 
mydriatic, Tropicamide ophthalmic solution 1.0%, and evaluated the change in pupil 
diameter over a 3 hour period.  They observed the peak action in about thirty minutes for 
each case and there was no significant difference in average pupil diameter between that 
of the mist and that of the solution.  Essentially, they found that despite delivering 1/5th 
of the volume of solution at the same concentration; they could produce identical clinical 
responses.  The device used in the proof of concept testing was a prototype, and because 
the geometry of the mist plume beyond 2 cm was amorphous, the authors were unclear as 
to the exact amount of drug substance reached the surface of the eye(93).   Nonetheless, 
the efficacy of the mydriatic mist was demonstrated to be within the suggested 
bioequivalence standards of the FDA, but larger more controlled studies would need to be 
conducted to make this conclusion. 
 
Modified Respimat ® (Boehringer Ingelheim) 
 The modified Respimat® device generates a slow moving aqueous spray 
and was previous developed by Boehringer Ingelheim for use as an inhaler.  It was 
recently been investigated for use in ophthalmology as topical delivery device.  
Diestelhorst et al. evaluated the microspray device in 20 total patients that had either 
glaucoma, dry-eye or were healthy volunteers.  They found that the microspray device 
was superior to eye drops in terms safety, tolerability and handing (94).  In another study 
investigating the bioavailability of fluorescein,  researchers found the microspray to have 
a much higher bioavailability (95).  The authors suggest the use of this device can simply 
topical therapy and could improve adherence.   
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  This aqueous spray was originally developed as a combination product 
used in pulmonary drug delivery.  The aerosol is generated by using a heavy duty spring 
to force a small metered quantity of liquid through various micro-channels within the 
device, called the uniblock.  Within these channels the liquid is accelerated to form into 
high velocity jets which impinge each other upon exiting in order to break up the liquid 
into fine micro-droplets.  In addition, these impinging jets also aid in reducing forward 
velocity, resulting in slow moving aerosol.  The Respimat® had unique advantages over 
other aerosol devices in that the plume developed much slower than traditional 
pressurized metered dose inhalers.  This feature also bodes well for use in topical ocular 
drug delivery as droplet size and impaction force will both contribute to patient comfort.  
Compared to other metered sprays the aqueous droplets produced by the Respimat® 
device are much smaller, with a mass median aerodynamic diameter of only 2 µm(96).  
While metered pump sprays, such as those used in nasal delivery, produce droplets that 
typically have an X50 of between 20 - 50 µm (97).   
 One of the unique advantages of using the Respimat® for pulmonary drug 
delivery was that because it generates a slow moving plume, it can reduce the amount of 
droplet that impact the back of the throat the patient.  In addition there is a decreased 
reliance on timing the inhalation maneuver compared to pressurized metered dose 
inhalers.  This improves dosing reproducibility and thus improving the overall delivery to 
the lungs.  However, this slowly developing aerosol could turn out to be a downside for 
use in ophthalmology as the duration of the plume generation needs to be faster than a 
typical blink response.  Otherwise, patients would need to hold their eyelids open 
manually.  Also, special care needs to be taken so the aerosol is moving fast enough to 
impart inertial deposition but not so fast as to cause damage to the ocular surface or any 
discomfort to the patient.  Furthermore, because the aerosol plume generated is the shape 
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of a cone, as the distance from the nozzle increases the larger width of the plume and the 
lower the concentration of the droplets becomes.  This increased distance ultimately leads 
to low ocular deposition, which Newman et al. documented while assessing the miss-use 
and off target effects of the Respimat® when used for inhalation (98).  To further 
optimize the use of this device for use in ocular drug delivery, modifications to the 
geometry of the plume would need to be made so that the majority of the dose would 
impact the ocular surface with a comfortable impact force and not deposit on the 
surrounding eyelids and face.  Overall, with a few modifications this device shows 
promise as a useful tool for delivering small volumes of liquid to the surface of the eye. 
  
Sprays/Vaporizers onto Closed Eyelids: 
 In addition to applying topical sprays or mists to the surface of the eye, 
scientists have also investigated applying these sprays to the eyelids of closed eyes.  
While the spray will not be directed onto the eye surface, the liquid can come into contact 
with margins of where the eyelids meet.  The medicament can then wick into the 
precorneal film and disperse locally (99).  Early investigations showed that using this 
technique can increase the residence time because the active can be retained at the 
interface of the eyelids and the tears (100).  In addition, this method overcomes some of 
the coordination problems that are associated with eye drop instillation technique.  This 
strategy has shown some benefit in reducing potent drug exposure in pediatrics(48).  
However, there is a large amount of controversy with these closed eye sprays, because 
the inherent variability of applying the medication in this form and the possibility of 
irritation on the surrounding tissue.  
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Tunable Aerosols: Drug Loaded Toroidal Vortices (Aerosol Vortex Rings) 
New research out of the University of Texas at Austin is focused on utilizing the 
coherent geometry associated with toroidal vortices in order to deliver aerosolized 
medication to the surface of the eye.  These ‘smoke ring’ vortices are well known for 
their reproducible structure and offer a unique opportunity for controlling aerosolized 
drugs over a distance suitable for treating the eye.  Typical aerosols are emitted as 
turbulent jets, with little or no control of the plume after it is emitted.  These turbulent 
plumes tend to spread out in an erratic, often unpredictable fashion.  Theses vortices 
however, maintain their structure and are able deliver micron sized droplets to the eye 
surface in a tunable and precise manner.  Figure 1.10 depicts a drug loaded toroidal 
vortex prior to impacting the ocular surface (101).  Because the aerosols produced from 
this device can be generated independent of the actuation, the velocity of the droplets 
throughout the geometric space of the plume can be tightly controlled.  This high level of 
control allows for tunable deposition, thus improving accuracy and precision (101).  
Furthermore, these droplets are moving at a rate fast enough to reach the eye before any 
blink reflex but because the droplets are so small they impact the surface with a minute 
impact force.  This technology could have big advantages for improving bioavailability, 
reducing systemic effects and even improve patient ease of use for those that have 
difficulty maneuvering standard eye drops.  A large number of drugs can be formulated 
into this device, but because the volume of delivery is small, drugs that require large 
doses could require multiple doses. 
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Figure 1.10.  Image of a Toroidal Vortex Prior to Impaction on a Prosthetic Eye. 
 
 
 
CONCLUSIONS: 
 
 While drug delivery to the eye is rife with challenges, many of the 
strategies and technologies highlighted herein offer a large number of solutions.  As 
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advances are made in pharmacogenomics and patient centered drug design begins to take 
center stage, a similar approach must be taken from the dosage form and delivery device 
design aspect.  With these advances in material sciences, microelectronics, smart 
polymers - safe, accurate and precision drug delivery is becoming more of reality.  The 
future of medical care of the highest caliber hinges on contributions from multi-
disciplinary scientific and engineering fields.  All of which together can make great 
advances solving some of the multi-faceted and complex problems in modern medicine.  
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Chapter 2.   Research Objectives 
 
 
OVERALL OBJECTIVES 
 
As continued progress is made advancing and developing new therapeutic 
compounds to treat vision threatening disease, there is an equally important need to 
develop new and effective drug delivery technologies to ensure safety, efficacy and 
ultimately improved therapeutic outcomes.  The primary objectives of this work were to 
investigate the use of aerosol loaded toroidal vortices for ocular drug delivery and to 
explore their potential roles in improving the standard of care.     
 
SUPPORTIVE OBJECTIVES 
 
The first aim of this research was to characterize all of the physical characteristics 
of the toroid generating drug delivery device and to determine which features of the 
device are responsible for controlling dose output and performance. 
 
The second aim of this research was to investigate different formulation strategies 
for incorporating poorly water soluble drugs into aqueous based vehicles, so that they 
may be optimized for use in the ocular drug delivery device.    
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SECTION 2:  DEVICE MECHANICS AND PERFORMANCE 
Chapter 3 :  Precision Ocular Drug Delivery Via Aerosol Ring Vortices 
 
ABSTRACT 
Despite being the most prominent dosage form for topical ocular delivery, eye-
drops have several well known drawbacks.  In this work we introduce a novel method to 
accurately and comfortably deliver ophthalmic medications to the surface of the eye.  We 
discovered that by aerosolizing a medicament and dispensing it in the form of a toroidal 
vortex, commonly known as a “smoke ring”, some of the major drawbacks associated 
with topical drug delivery can be avoided.  It was found that the dose delivered to the 
surface of the eye was directly proportional to the velocity and the size of the droplets 
emitted from the device.  With a dilute solution, 0.05% fluorescein, doses could be 
reproducibly deposited by actuating the device at low velocity (~5 ng) and at high 
velocity (~18 ng).  While with more concentrated solutions of 0.5% Fluorescein, between 
20 and 160 ng could be deposited depending on selected actuation velocity.  And with the 
highest concentration, 5% Fluorescein, 1.15 +/- 0.075 µg was deposited.  In addition, the 
amount of drug deposited onto the eye surface was shown to be modulated by changing 
the chamber fill time.  Precise toroidal vortex based aerosol delivery may facilitate 
optimized administration of medicines to the surface of the eye. 
 
INTRODUCTION 
The increasing prevalence of diseases associated with an aging patient population, 
especially in areas of ophthalmology and eye care have highlighted the need for 
 66
improved delivery systems.  By far the most common method for delivering drugs the 
eye is the eye drop.  While there is direct access to the eye, there are several formidable 
barriers preventing effective, efficient and/or convenient administration of the medicine.  
Indeed, eye drops are well known for having very low bioavailability; in some cases 
significantly less than 1% of drug is delivered at the desired ocular tissues (1, 2). This is 
well studied and is due to the multitude of physiological barriers that exist to protect the 
visual system, as well as the mismatch in the capacity of the eye to hold the instilled 
liquid contained within an eye drop.  The pre-corneal film can only stabilize about 7 µl, 
yet a typical eye drop is on the order of 50 µl, and can range from 20 – 75 µl (3). This 
results in the majority of the eye drop immediately spilling over onto surrounding skin on 
the eyelids and/or it is rapidly cleared via the nasolacrimal drainage.  Furthermore, the 
added liquid from the eye drop instigates further tear production promoting accelerated 
rinsing of the eye (4).  Upon drainage the drug can be absorbed via the nasal cavity and 
enter the systemic circulation where potentially toxic off-target effects can occur, 
especially in pediatric populations (5-7). 
Because of the highly protected nature of the eye, pharmaceutical scientists have 
proposed various formulation strategies to overcome these barriers.  The two main 
principles for improving ocular bioavailability are increasing the permeation of the drug 
via permeation enhancers, transporter coupling or even modifying the drug’s chemical 
structure to serve as a pro-drug with better pharmacokinetic properties (8, 9).  Another 
approach is to increase the residence time of the drug with the relevant membranes (10).  
Increasing the residence time can be accomplished via many different methods such as: 
increasing the viscosity the formulation, incorporating mucoadhesive polymers, 
nano/microparticulates for mucin entanglement or even by using drug loaded ocular 
inserts, which reside semi-permanently in the ocular cavity. 
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Beyond the aforementioned strategies another method has been shown to improve 
the residence time in the pre-corneal film.  It was as early as 1973 when Chrai et al. first 
published the correlation between instilled drop size and pre-corneal residence time (11). 
While studying the tear film formation and turnover he noted that as the volume of the 
drop instilled decreased, the longer it remained in the film.  Since then many others have 
investigated this phenomenon (12-15).  It has been proposed that by reducing the 
instillation volume, the reflex tearing and clearance mechanism is significantly reduced 
and subsequent improvements in bioavailability can be achieved (16, 17).  Furthermore 
this reduced reflex tearing and drainage also reduces or eliminates unwanted systemic 
effects by reducing the amount of drug that enters the nasolacrimal system.  While 
reducing drop volume is a promising strategy, there has been technical difficulty in 
developing systems in with patients can safely self administer micro sized volumes 
accurately either because of the technical complexity, variability of the spray plume or 
because risks associated with fine tipped droppers (18, 19).   
One of the challenges with delivering small volumes is in the limit of the droplet 
size.  Because of the surface tension in water it is difficult to form fine droplets, so 
typically large amounts of energy are required to overcome surface tension and aerosols 
are produced with high velocities and /or amorphous plumes that are difficult to control.   
In this study we investigate a novel drug delivery device that is capable of 
delivering very small volumes via aerosol droplets for deposition onto the ocular surface.  
This device generates micron-sized droplets and forms them into a highly structured 
toroidal vortex (i.e. smoke rings) in order to precisely and reproducibly administer a drug 
to the ocular surface (as depicted in Figure 3.1).  Unlike other sprays or mists which are 
difficult to direct due to the variability of the plume geometry and speed, these smoke 
rings hold together enabling additional control of the deposition.  We investigate herein 
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the main device features that influence the device performance in regard to in-vitro drug 
deposition in hopes to fine tune the delivery for future pre-clinical testing. 
 
 
Figure 3.1.  Image of a Drug Loaded Toroidal Vortex prior to impacting the surface of a 
prosthetic eye (Smyth and Herpin, 2015) 
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MATERIALS & METHODS 
 
Generation of Fluorescein Loaded Toroidal Vortices.  
 
The formation of the toroidal vortex vehicles were separated into two steps, (1) 
the generation of the aerosol and (2) the actuation of device.  To form the aerosols we 
first prepared three solution formulations using sodium fluorescein (Sigma-Aldrich, 
USA) as the tag/model drug dissolved in isotonic phosphate buffered saline at pH 7.4 ( 
Sigma-Aldrich,USA ).  These formulations were selected in order to cover a 100x change 
in concentration, from 0.05% to 5%, which represents a large spectrum of potential 
starting solution concentrations.  The formulations were loaded into the sample cup of the 
Omron MicroAir® Nebulizer model: NE-U22, and the nebulizer was mounted onto the 
toroidal vortex device actuator.  To control the aerosol chamber fill time, a stopwatch was 
synchronized with the manual activation of the aerosol generator.  Upon filling the 
aerosol chamber with predetermined amount of aerosol the device was actuated with a 
predetermined force.   
To actuate the device a calibrated customized pendulum equipped with a 
precision protractor for measuring set heights was used to vary the actuation force.  The 
actuator device membrane was positioned in-line with the pendulum at the 90º, allowing 
for an accurate horizontal impaction force to be delivered the membrane and initiate the 
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toroid formation (see Figure 3.2).  When the membrane is actuated using the pendulum, 
the forward displacement generates an instantaneous pressure increase within the 
chamber and induces flow into the gas in which the aerosol droplets are suspended.  This 
results in the aerosol exiting through the device orifice.  The initial fluid flow at the edge 
of the orifice creates an area of low pressure (i.e. a vortex) along the pathway of the 
orifice.  This results in the formation of a circular vortex also known as a toroidal vortex 
or more commonly known as a ‘smoke ring’.  The emitted vortex can then be 
characterized in terms of velocity and droplet size distribution, and in-vitro deposition.   
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Figure 3.2.  Ocular Drug Delivery Device attached to a Calibrated Actuator(20). 
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Vortex Translational Velocity  
 
To investigate the relationship between impaction force and toroidal vortex bulk 
velocity, we utilized an analogous method to that of Hochrainer et al., known as the “dark 
field technique” (21).  For this method, the device was placed in a dark box and aligned 
with a spatial calibration target.  The pathway for the emitting vortices was illuminated 
by a laser sheet and then the device was actuated at various relative forces using the 
pendulum. As the aerosol is emitted the droplets are illuminated by the laser sheet and a 
high speed camera was used to capture the video recordings at 200 frames per second. 
The digital images were processed using front edge of the vortex to track the velocity of 
the propagating vortex.  The velocity measurements were done using Kinovea Video 
Analysis software. 
 
 
Deposition Studies: Inertial Impaction Simulations 
The deposition of entrained droplets onto a surface is a very important parameter 
for the performance of the device as it will indicate the dose delivered to the eye.  The 
deposition mass is the amount of drug that leaves the toroidal vortex upon impaction on 
the surface of the eye.  In initial testing a prosthetic eye was used to simulate geometry of 
the eye to achieve spatially similar impaction.  For screening studies we utilized next-
generation inertial impactor (MSP Corp, MN) impaction plates as the substrate.  These 
impaction plates are designed for inertially collecting aerosols during analogous testing. 
 The device outlet was fixed at a distance of 3 cm from the plate.  The aerosol chamber 
was filled for predetermined and varied amounts of time with each formulation.  The 
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device was actuated at a range of actuation forces in order to assess the effect of chamber 
fill time and actuation force on aerosol deposition.   
 
 
Quantification of droplet deposition  
The impaction plates/deposition substrates were rinsed with adequate diluent and 
assayed for mass deposition by fluorescence spectroscopy with a 460 nm excitation 
wavelength and a 515 nm emission wavelength, using the Tecan M200 Microplate 
Reader. 
 
Particle/Droplet Size Distributions 
The droplet size and distribution of the aerosols produced from the device was 
measured using a Sympatec Helos laser diffraction apparatus (Clausthal-Zellerfeld, 
Germany).  The aerosol was emitted directly into the laser beam at ambient conditions.  
The laser diffraction pattern was collected using the R3 lens (f= 100mm) and the 
calculations were done using Fraunhofer theory with the Sympatec Windox 5 software.   
 
RESULTS AND DISCUSSION 
 
Formation of Toroidal Vortex Rings 
 
In order to generate drug loaded toroidal vortices two main actions were 
necessary.  Firstly the device chamber needs to be filled with an aerosolized formulation 
and secondly, a force applied to actuate the device.  In our case we used a vibrating mesh 
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nebulizer as source of reproducible droplets that are in the size range desired.  The 
Omron MicroAir NE-U22 device utilizes a horn transducer that oscillates at 180 kHZ.  
This horn is adjacent to a micro-perforated mesh with approximately 6,000 holes (22). 
The solution sample is pumped from a reservoir through the mesh which is directly in 
contact with allowing for small sample volumes to be utilized.  The aerosol produced 
from the generator fills the loading chamber just prior to device actuation.  Figure 3.3 is a 
close up graphic showing the device a emitting toroidal vortex from the orifice which is 
directly adjacent to chamber from whence it is dispensed.  This allows for rapid chamber 
filling and subsequent ejection.  Finally, the large rim of the device is the eye-piece.  This 
is used to correctly position and space the device relative to the eye, as well as to assist in 
holding the lower eyelid in place to prevent blinking.   
 
Impaction on the Ocular Surface: 
 
In Figure 3.1, the relative size of the toroidal vortex to ocular surface can be 
shown.  Keeping in mind that the majority of sclera will be covered by the upper and 
lower eye-lids, the cornea however is the portion directly covering the colored iris and is 
predominantly exposed.  The geometry of these toroidal vortices was designed so that the 
impaction portion would be directly centered with that of the cornea.  In the case of 
administering this dosage form, the device is aligned via the surrounding eye-cup 
depicted in Figure 3.3 , where the eye- cup is placed onto the ocular orbital comparable to 
looking into a binocular eye-piece.  In addition the lower eye-lid may need to be held 
down briefly in order to maximize the available surface.  This is comparable to what is 
done with eye-drop applications however in this case the head will not be required to be 
tilted backward as the dosage is an aerosol which disperses into the existing tear film. 
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Figure 3.3.  Illustrative depiction of the ocular drug delivery device emitting an aerosol 
loaded toroidal vortex 
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In-Vitro Deposition Analysis 
 
In preliminary testing, an ophthalmic prosthesis was used as a substrate for 
deposition because of the analogous geometry.  The extraction of the deposited material 
from the prosthetic introduced sources of error attributed to extraction efficiency.  
Therefore, to assess the in-vitro deposition of the output from the device we utilized Next 
Generation Impactor testing plates.  These plates are designed for the capture of 
impinging aerosol streams used in the assessment of aerodynamic diameter for 
aerosolized dosage forms.  It has been suggested that the surface roughness may play a 
role in deposition ballistics (23). These plates are manufactured to a have specific surface 
roughness as per USP compendia to be between 0.5 and 2 µm.  In addition, these plates 
are easily grounded to reduce any effect of electrostatics in that could be generated with 
electrically insulating components during the course of this assay (24). 
To conduct the deposition analysis, the device was placed a distance of 3cm from 
the plate.  This distance was selected as it provides adequate time for the toroidal vortex 
to fully form and propagate towards the eye.  It is also no so far that the dynamics of the 
toroid are disrupted due to turbulence.  The device was filled with aerosol and actuated to 
produce toroids moving at different velocities.  The range of velocities screened for 
deposition was such that at the lowest velocity to form a vortex by this mechanism all the 
way to the top end where the toroidal vortex breaks down into a turbulent jet.  Others 
have been able to produce stable vortices with higher velocities via different actuation 
mechanisms, for evaluation of different phenomena, for our purposes these ranges suffice 
(25). 
The main purpose of this experiment is to understand the relationship between 
toroid velocity and deposition onto a substrate.  Aerosols have 4 main mechanisms for 
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depositing: inertial impaction, sedimentation, intersection and diffusion (26-28).  In 
addition there are several other mechanisms for deposition such as thermophoresis and 
electrostatics which at this point these mechanisms are beyond the scope of this article.  
We hypothesized that the deposition of the droplets would be proportional to the velocity, 
as the velocity component of momentum in the equation, momentum = mass x velocity, 
is proportional to the mass and thus the inertial of the droplets.  In addition, in these 
experiments we were not altering the size/mass of the droplets at each velocity, so any 
possible changes in deposition would likely be correlated with velocity.  As can be seen 
in Figure 3.4, with the 0.05% fluorescein solution, as the velocity increased, the amount 
of fluorescein deposited also increased.  At the lowest velocity, about 5 ng was deposited, 
while at the highest velocity between 12 and 18 ng was deposited.  Likewise intermediate 
velocities showed intermediate deposition.  This is a useful finding as it reveals that with 
a constant chamber fill time the amount of aerosol that is emitted should be constant, yet 
more of the emitted aerosol is impacted onto the surface.  This indicates a much higher 
deposition efficiency at higher velocities.  This same effect was more exaggerated at the 
higher drug loading concentration of 0.5% (Figure 3.5).  At this concentration the 
minimum deposition was approximately 20 ng and the maximum was about 160 ng.  This 
shows a nearly 10X increase in deposition just based off the toroid velocity.  In addition, 
this shows that with just 2 different formulations a nearly continuous range of deposited 
quantities can be achieved by altering the device actuation force.  
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Figure 3.4.  In-Vitro Deposition Analysis.  0.05% Fluorescein.  Fluorescein Deposition as 
a Function of Toroid Impaction Velocity and Chamber Fill Time.      
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Figure 3.5.  In-Vitro Deposition Analysis.  0.5% Fluorescein.  Fluorescein Deposition as 
a Function of Toroid Impaction Velocity and Chamber Fill Time. 
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Chamber Fill Time: 
 
Another aspect of this study was to investigate the effect of chamber fill time on 
the amount of drug deposited.  We hypothesized that as the chamber fill time increased, 
the number of droplets in each toroid would also increase therefore increase the available 
number of droplets to be deposited onto the surface via impaction.  For the 0.5% solution 
at each toroid velocity, as the chamber fill time increased the deposition increased Figure 
3.6.  However, in the case of the more dilute formulation, 0.05% fluorescein, the 
deposition did not increase as drastically over the range of chamber fill times Figure 3.7. 
 This is due to the diminished amount of drug being added per quantity of time in dilute 
solutions.  A 1, 3 and 5 sec fill time only allows for a small quantity of drug to be added 
at a fixed nebulization rate.  At a fixed nebulization rate droplets are being formed 
continuously and each new droplet only slightly contributes to an increase in deposited 
drug mass.  On the other hand, while each second with a concentrated solution 
nebulization rate contributes much more drug by droplet volume/density (i.e. higher drug 
payload per droplet/time). 
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Figure 3.6.  0.5 % Fluorescein Deposition as a Function of Chamber Fill Time at 
Different Actuation Forces. 
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Figure 3.7.  0. 05 % Fluorescein Deposition as a Function of Chamber Fill Time at 
Different Actuation Forces. 
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Dose Uniformity under Upper Loading Conditions 
 
To determine the amount of drug deposition that can be achieved when using a 
more concentrated 5% fluorescein sodium solution, the device was loaded for 5 seconds 
and actuated at the highest velocity.  With this concentration, the device was able to 
deposit 1.15 µg +/- 0.075 µg.  While this is a relatively small mass of drug overall, it will 
be instilled into the very small volume of the tear film.  This could theoretically result in 
a very high local concentration and contribute strongly to establishing a large diffusion 
gradient.  Furthermore, because the eye is such a small organ this quantity of mass is on 
the order of what is need to achieve adequate EC50s for many commonly used 
ophthalmic medications, assuming the drug is sufficiently permeable.  Our lab intends to 
focus future investigations in exploring the ex vivo/in vivo pharmacokinetics of these 
micro-volume instillations. 
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Figure 3.8.  Deposited Dose Uniformity from 5% Fluorescein, with a 5 Second Chamber 
Fill Time. 
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Particle/Droplet Size Distributions (PSD) 
 
The production of droplets for use in this device is done achieved with a vibrating 
mesh nebulizer.  While many different types of aqueous aerosol generators may be used 
to provide aerosols with adequate characteristics, he vibrating mesh nebulizer here 
(OMRON MicroAir) produces uniform and reproducible droplets which tend to be robust 
in size for differing formulations (29, 30).  Use of these nebulizers in the eye is new area 
of research, however several others have investigated the formulation affects on droplets 
size and output rate in regards to pulmonary drug delivery (31-34).  Here in these studies 
we are primarily concerned with large changes in size that could affect the settling 
time/chamber fill time ratio.  In that when droplets become too large they tend to settle 
more rapidly, as described by Stokes’ Law, and it is crucial that droplets are suspended in 
the chamber long enough to be ejected in the toroidal vortex.  On the other hand, the 
droplets cannot be so small that they are not easily ejected from the vortex upon 
impaction onto a surface.  
Altering the concentration of the drug in the solution will have an effect on the 
physical chemical properties of the solution and its interaction with the vibrating mesh 
could alter the size of the droplets, we analyzed the droplets size distribution for each of 
the formulations.  As can be seen in Figure 3.9, the sizes are nearly identical for each of 
more dilute solutions (0.05% and 0.5%) with the mode being right after about 5.5 µm. 
 The main difference in PSD between the formulations is that the dilute solutions, 0.05 & 
0.5 % have a more broad distribution with larger tail on the large size end, and the highly 
concentrated, 5% solution, had a much more narrow PSD spread.  In Table 3-1 the data 
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shows the 0.05% and 0.5% solutions to have nearly identical cumulative makers, with 
X50 of ~ 5.8 µm, an X10 of ~1.4 µm, an X90 of ~14.5 µm, and with a volume mean 
diameter (VMD) of about 7.1 µm.  As for the most concentrated solution, 5% 
Fluorescein, the particles size distribution was shifted toward the smaller size, largely due 
to the reduction of the tail.  This decrease in droplet size could be attributed to a change 
in surface tension, and be explained by Tate’s Law (32, 33, 35).  Furthermore, because 
the solution is much more concentrated, other contributions from ionic strength or 
changes in micro-rheology cannot be ruled out. Nonetheless, all the droplets produced in 
with the vibrating mesh nebulizer were small enough to form stable aerosol clouds by 
visible inspection and none of droplets were so large as to settle before being ejected 
from device.  
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Figure 3.9.  Particle/Droplet Size Distributions of the Aerosols Produced from 3 different 
Fluorescein Formulations. 
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Table 3-1.  Fluorescein Formulations with Particle Size Distribution Data Measured by 
Laser Diffraction 
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Currently aerosol generating devices are designed in order to produce droplets in 
the 1- 5 µm range so that they can navigate the pulmonary system and be deposited into 
the deep airways.  If they are too large they deposit in the mouth and throat and if they 
are too small they are exhaled.  A similar challenge exists in designing aerosol for topical 
impaction.  The droplets need to be small enough to be entrained into fluid vortices but 
also need to be large enough to carry enough inertia for deposition and to deliver an 
adequate payload.  However, the droplets cannot be so large they rapidly settle or unable 
to be entrained in the fluid flows.  The vibrating mesh technology is well suited for this 
application because the size of the laser drilled holes in the mesh are highly correlated 
with droplet size and can be easily altered for different formulations.  As can be seen in 
data present in this article the droplet size and distributions can be altered slightly, but for 
the most part the range is adequate for our ophthalmic purposes.  
 
CONCLUSION 
 
In this study we were able to successfully produce drug loaded toroidal vortices 
containing a model drug fluorescein, and characterize several of the key features of the 
device and how they relate to in-vitro performance.  Furthermore we established the 
relationship between drug deposition and vortex velocity in hopes to determine the most 
adequate ejection velocity for future drug delivery attempts.  Many of the control features 
such as chamber fill time and ejection velocity appear to offer a direct means for tuning 
drug delivery doses from the device.  This should allow for a highly tunable delivery 
mechanism that could be altered to accommodate a large number of medicinal agents at a 
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wide range of concentrations.  While in-vitro testing reveals the device is capable of 
precision delivery, ex-vivo or in-vivo testing would need to be done in order confirm if 
the delivery to the ocular surface is in fact just as precise.  Furthermore, in-vivo 
pharmacokinetic analysis would need to be done in order to establish if this device offers 
any additional enhancement in bioavailability as predicted by the theory and 
demonstrated by other methods.  
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Chapter 4 :  Characterization of Drug Loaded Toroidal Vortices 
Intended for Ocular Drug Delivery 
ABSTRACT 
For the last several decades the predominant method for delivering medicine to 
the surface of the eye has been the standard multi-use eye drop.  While being the most 
popular, this method has significant limitations.  Recently an effort has been made to 
explore the use of a toroidal vortex or “smoke ring” aerosol delivery system that may 
help overcome these limitations and enable delivery specific amounts of formulation and 
drug to the ocular surface.  Previous studies have shown that reproducible quantities of 
medication can be deposited in vitro; however, the physical characteristics of the aerosol 
output in regards to device performance and patient comfort have yet to be established.  
Here, we investigate the mechanics and the nature of these vortices, such as translational 
and rotational velocity, regional droplet size distributions and relative impact force in 
order to optimize the performance and evaluate their clinical relevance as a drug delivery 
vehicle for future investigations.  Maximal droplet velocity at various actuation forces 
was determined, and they were all less than 6 m/s even at the highest actuation forces.  
Moreover, plume impaction forces were determined and were all less than about 4.5 
micro-Newtons.  Collectively, these studies showed that the physical and mechanical 
properties of the emitted drug loaded vortices would be suitable for ocular administration.  
 
INTRODUCTION 
The increasing prevalence in the age related disease is especially notable in 
ophthalmology.  It is estimated that between 1 - 4% of all patients over 45 years of age 
will be diagnosed with glaucoma (1). And between 6 - 22% patients over the age of 70 
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years will be afflicted with age-related macular degeneration (2). These ocular diseases 
are the two leading causes of blindness in the United States, which collectively, major 
visual disorders cost $35.4 billion annually, and is expected to further increase with an 
aging patient demographic (3). 
 Despite new ophthalmic drug candidates to treat glaucoma and retinal 
disease, large barriers to their effective delivery to the target tissues still remain.  This is 
due to the highly protected nature of the ocular/visual system and its crucial role in 
survival throughout the evolutionary process.  Beyond the physical structures in the eye 
such as the cornea, sclera, iris, and cilliary body that can obstruct the diffusion of drugs 
from the front of the eye, there is also blood-retina barrier, and the blood-aqueous barrier.  
These barriers limit the entry of drugs from the blood stream so that many systemically 
circulating medications do not achieve adequate concentrations in the ocular tissues (4). 
The eye is also guarded with a reflex blinking and flushing system from the anterior.  
This system drastically reduces the amount of time a drug has to diffuse across the 
barriers of the front of the eye.  Conventional ophthalmic drug delivery systems such as 
viscous solutions, suspensions, gels and ointments attempt to increase the residence time 
and thus the exposure, to improve absorption.  However, due to the difficulties in 
administration and increased blurring of the vision, patient compliance becomes an issue.  
Other, more non-conventional forms such as ocular inserts or drug eluting punctal plugs 
have also been investigated and used for the purpose of decreasing dosing frequency and 
improving bioavailability (5). While these have shown to be promising they have 
limitations in that they can be inadvertently ejected from the eye which often requires a 
doctor’s visit to reinstall the device.  In addition, some patients complain of discomfort in 
wearing them, so at this point they have not been able to provide an overall solution yet.  
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Recently pharmaceutical scientists have investigated the potential use of 
ophthalmic aerosols to deliver medications to the eye.  In a clinical trial assessing mean 
maximal pupil dilations in 100 patients, Collins et al. found no significant difference 
between eye drops and an ophthalmic aerosol administered topically (6).  Moreover, 
others have previously shown improved drug bioavailability from smaller volume 
instillations (7-11).  In addition, the use of small volume instillations can significantly 
reduce the overall drug exposure to the patient and potentially eliminate or reduce some 
off-target effects, which is especially important in pediatrics (12-15).  
Our laboratory has recently developed a method to deliver medications to the 
surface of the eye via aerosols which are formed into toroidal vortices (e.g ‘smoke rings’) 
that enabled accurate and controllable delivery of small volumes (16). Because this 
method of delivery is significantly different from other aerosol or small volume 
approaches tested previously, we investigated here, several different analytical techniques 
for the characterization of this aerosol delivery system.  This delivery technology 
produces micron sized droplets containing dissolved drug, moving at variable velocities.  
Therefore advanced analytical methods needed to be adopted to characterize this dynamic 
system.   
The objective of this study was to characterize all of the clinically relevant 
physical performance features of this delivery device, in order to determine if the device 
performs in a safe comfortable and reliable manner for future clinical investigations.      
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MATERIALS AND METHODS: 
Materials: 
The Omron MicroAir NE22 vibrating mesh nebulizer was graciously donated by 
Omron Corp.  EZ-Breathe Atomizer (Nephron Pharmaceuticals, Orlando, FL) was 
purchased OTC.  All formulations utilized isotonic phosphate buffered saline, PBS 
(Sigma), or PBS and Fluorescein Sodium which was purchases from Spectrum Chemical 
MFG Corp., USA.  And the ocular toroidal vortex generator was custom fabricated in 
house. 
Methods: 
Device Actuation for the Generation of Toroidal Vortices 
Generating toroidal vortices from this ocular drug delivery device is based off two 
key major actions/steps, (1) the aerosol generation and (2) the ejection of the droplets.  
Aerosols were loaded into the chamber portion of the device via two different vibrating 
mesh aerosol generators, the Omron MicroAir NE-U22 and the EZ-Breath Atomizer.  
Once the chamber is adequately filled with the desired amount of aerosol, a 12-volt push-
pull type solenoid (Adafruit,USA) is activated in order to impart a force wave onto the 
actuating membrane.  And a variable voltage controller was used to alter to the actuation 
energy supplied to the membrane actuator and thus alter the exit velocity of the toroidal 
vortices.  This device actuation mechanism is illustrated in Figure 4.1. 
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Figure 4.1.  Illustration of the Actuation of the Ocular Delivery Device. 
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Determination of the Maximal Droplet Velocity within the Toroidal Vortex 
 
Stereo Particle Image Velocimetry:  
High-speed stereoscopic particle image velocimetry (PIV) was utilized to measure 
the velocity field in a plane cutting through a propagating toroidal vortex with nebulized 
droplets entrained within.  We generated a laser beam with a high-repetition rate Nd:YLF 
laser (Coherent Evolution 90) that was then formed into a thin sheet with bench top 
optics. This laser sheet was used to illuminate the droplets within the toroidal vortex at a 
frequency of 5 kHz to obtain a velocity field every 200 μs.  This laser sheet is 25 mm 
wide and aligned with the device orifice (nozzle) to allow for tracking the velocity as it is 
generated to a distance of 25 mm.  The spatial orientation can be seen in Figure 4.2.  
Furthermore, two high-speed Photron APX cameras fitted equipped with Nikkor 105 mm 
lenses with an f/5.6 aperture were fixed at an angle focused toward the propagation path 
of the toroids in order to capture any out-of-plane motion. 
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Figure 4.2.  Schematic of the Experimental set-up of Stereoscopic Particle Image 
Velocimetry 
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The investigational space was calibrated with a dot target of known dimensions so 
that a mapping function between pixel location on camera and physical space could be 
established.  The cameras were synchronized with the laser to capture light scattered off 
of the droplets at 5 kHz at a resolution of 5122 x 5122.  For PIV processing the images 
were divided into 162 x 162 interrogation windows with 50% overlap.  The particle 
images in subsequent interrogation windows over time are cross-correlated to obtain the 
particle displacement.  The velocity vector is obtained from the particle displacement and 
the time delay between two subsequent laser pulses (200 μs).  We used the DaVis 8.2 
Software package by LaVision to perform PIV processing at a spatial resolution of 0.055 
mm/pix, which leads to a measured velocity vector every 0.45 mm allowing for well 
resolved velocity fields throughout the internal dimensions of the vortex.  
 
Toroidal Vortex Translational Velocity 
In order to determine the velocity at which the entire toroid propagates a different 
approach was taken.  The high-speed image sequences allow for temporally resolved 
measurement of the velocity by mapping them to physical space via the pinhole 
calibration previously mentioned and employing Matlab in conjuction with its image 
processing toolbox.  The velocity of the toroidal vortex is determined based on tracking 
the front edge of the toroid over time, this comparable to what others have done using the 
“Dark Field Technique” to characterize metered dose inhalers (17).  Except in this case 
the front edge detection was automated and based off an intensity threshold.  And the 
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velocity evolution was obtained by a sliding linear curve fit to the change in position over 
time. 
Droplet Size Analysis 
The aerosols produced from this device were characterized for particle/droplet 
size distribution (PSD) and optical concentration (Copt) by laser diffraction (Sympatec-
Helos) using the Fraunhofer (HRLD) and Mie Theory calculation methods and data was 
collected with used of an optical trigger.  The modular dispersing units were removed and 
the instrument was set-up in the ‘open-bench’ mode where the aerosol can be transmitted 
from the device directly into the beam path for analysis.  The instrument was set to 
collect PSD/Copt data at a 1 ms intervals throughout the duration of the toroid 
propagation.  A schematic how the vortices where analyzed is illustrated in Figure 4.3. 
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Figure 4.3.  Schematic Showing the Experimental Set-up for the Droplet Size Analysis of 
a Toroidal Vortex by Laser Diffraction. 
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Plume Impaction Force  
In order to assess the relative impact force generated by these toroidal vortices we 
custom-configured a Mettler Toledo XP26 precision microbalance.  The balance was 
connected via serial port to a computer with data-logging software.  The balance was 
configured into fast-host mode and balance measurements were streamed at the maximal 
sampling rate of 97/sec (Mettler Toledo manual).  The device was placed inside the glass 
wind cage and an additional wind shielding apparatus/stand was built to add further 
protection from convective wind and to align the device.  The device was actuated 
perpendicular to the balance plate at a distance of 3 cm in order to record direct 
deflections at a clinically relevant distance.  Peak balance deflections were recorded and 
plotted vs. actuation energy to resolve the correlation relationship. See Figure 4.4 for the 
experimental set-up. 
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Figure 4.4.  Schematic for Measuring the Relative Peak-Force Generated by Toroidal 
Vortices. 
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Results and Discussion 
When designing an ophthalmic drug delivery device several key features need to 
be investigated in order to ensure patient safety, tolerability, reproducibility, feasibility 
and ultimately efficacy.  The features of this device that have been identified to play a 
major role in the performance and feasibility of the device are related to the nature of the 
generated toroidal vortices and how a patient may experience them. The main features we 
investigate here are the components that can contribute to the patient comfort and 
usability.  The components that contribute the comfort of administration are all related to 
the nature of the impact of the droplets onto the eye, the velocity and size of droplets.  In 
addition, these parameters also influence the performance because there exists a balance 
between velocity and PSD for optimal deposition.  Furthermore, the feasibility of the 
device pertains mostly in the ability to deliver the medicine before an instigated blink 
reflex can block or disrupt the dose (18).  For this, the bulk velocity over a distance was 
mapped to determine if the velocity of the vortex is adequate to escape a possible blink 
reflex.  
We found that we able to successfully characterize the major characteristics of 
these toroidal vortices by use of very different high precision instrumentation/techniques 
such as: laser diffraction, high-speed stereoscopic PIV, and microbalance real-time data 
sampling.  Each of the methods discussed here help determine the clinical relevance and 
feasibility of using this device in patients suffering from various ocular diseases.  While 
these methods are currently being investigated for applications in ophthalmology, they 
could also be applied to investigate other aerosol or mist devices which create very small 
aerosol plumes.  This paper is primarily concerned with investigating the properties of 
these toroidal vortices and the relevant aspects the patient would directly experience, in 
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order to tune and optimize a final prototype device for further investigation in a clinical 
setting. 
 
Droplet/Particle Size Analysis and Optical Concentration 
 
Vortex Droplet Sizing 
It is expected that the nature of the droplets generated from this device to play a 
crucial role in the performance, because the droplet size can affect the deposition 
efficiency, dose payload and even the net impact force onto the ocular surface.  The 
manner in which these aerosols are produced from this device are very similar to that of 
those produced for normal pulmonary inhalation, except that these droplets are first 
accumulated into a loading chamber and then emitted through ambient space onto the 
ocular surface.  When generating nebulized aerosols for pulmonary inhalation, the patient 
would normally directly inhale the droplets as they are being generated.  And because the 
droplets produced from these nebulizers are very small, they are susceptible to the Kelvin 
effect, where the increased surface area causes an increase in the vapor pressure.  This 
causes them to evaporate quickly when below the vapor saturation point of the 
atmospheric phase (19).  But as they enter the environment in the lungs, where the 
relative humidity is near 100%, the evaporation can be reduced and even in some cases 
the droplets can grow due to the nonvolatile solute concentration and hygroscopicity (20, 
21).  In this case with a loading chamber, droplets are generated and accumulated within 
the chamber prior to being emitted.  Therefore we suspect there will be simultaneous 
evaporation/condensation as well as coalescence of the droplets within the chamber and 
as they are emitted there could be some evaporation.  To determine whether or not any of 
these events play a role we investigated droplet size and optical concentration as function 
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of both chamber fill time and distance from the orifice.  As reference point we selected an 
intermediate or a center point for the variables in inconsideration.  A chamber fill time of 
3 seconds, a actuation distance of 3 cm and an actuation voltage of 9 volts was selected.  
The characteristics of the toroids created under these conditions are shown in Table 4-1 ).  
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Table 4-1.  Droplet size data for toroids generated from a 3 second fill, 9 volt actuation at 
3 cm distance. 
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 Droplet Size and Optical Concentration as Function of Chamber Fill Time  
In order to generate drug loaded toroidal vortices by this method, the aerosol 
chamber but first be temporarily filled.  This allows for a predetermined amount of 
aerosol to be incorporated in the vortices upon actuation.  However, the as previously 
mentioned, there is likely simultaneous droplet evaporation/condensation as well as 
coalescence.  In order to assess the degree in which this may occur, we measured the 
optical concentration and droplet size characteristics for a fast and slow chamber fill time, 
corresponding to 1 second and 3 seconds.  The optical concentration can serve as in 
indicator of aerosol concentration or number of aerosol droplets per volume.  In addition, 
any change in droplet size would indicate if there was either evaporation or condensation 
occurring in the time frame in question.  The results are reported in Table 4-2 .  The table 
shows that between a 1 second fill time and a 3 second fill time there was virtually no 
difference in X10 and X50 fraction but showed a very small increase in the X90.  
However, there was a marked increase in optical concentration, from 3.01% to 11.95%.  
This increase is to be expected because the output rate of the nebulizer is constant and by 
increasing the fill time, the number of droplets/volume increases directly.  These findings 
are important because they show that despite increasing the number of droplets in the 
chamber, over the course of a 3 second period, (which is much longer than a typical 
chamber fill) there is not any appreciable evaporation or coalescence of droplets 
occurring in the chamber that translates to a measurable difference once the toroidal 
vortex is emitted from the device. 
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Table 4-2. Optical Concentration and Droplet Size as a function of Chamber Fill Time at 
a Distance of 3 cm and 9 volt Actuation. 
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Vortex Droplet Size Over Distance 
 
For practical purposes it not feasible to investigate the droplet sizes from within 
the device, and the most important feature is the size of the droplets as they approach the 
ocular surface.  So we investigated the effect of droplet size change as the vortex 
propagates from the orifice to a distance of 5 cm.  This distance is about the limit for 
practical applications in ophthalmology.  As can be seen in Figure 4.5 the X90 for the 
droplets decreases as the distance from the orifice increases.  More specifically, at 1 cm 
from the orifice the droplets have an X90 of ~4.25 µm and as the distance increases to 3 
cm, this valued drops just slightly, but at 5 cm the droplets are noticeably smaller with an 
X90 of ~3.25 µm.  To further investigate, the optical concentration as a function of time 
was also assessed.  We found that as the distance from the device orifice increased, the 
optical concentration also decreased (Figure 4.6).  These findings strongly suggest that 
there is some degree of evaporation occurring for these formulations as they propagate, 
but the change is relatively small over the distance of interest.  Furthermore, these results 
have provided insight that can serve as a guide to establish proper positioning of the 
device relative to the eye in order to minimize variability that could be caused by 
evaporation. 
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Figure 4.5.  Droplet Size (X90) Decreases as the Distance from the Orifice Increases. 
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Figure 4.6.  Toroidal Vortex Optical Concentration as a Function of Distance from 
Device. 
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The typical droplets produced from vibrating mesh nebulizers range on the order 
between 1- 5 μm and this range can shift a few micrometers to the larger or smaller end 
with some formulation changes.  However for them most part, the droplets produced 
from these nebulizers are largely dependent on the nebulizer characteristics such as mesh 
size and energy amplitude (22).  As can be seen in Table 4-1 (Toroid PSD-Table), when 
the toroidal vortex was measured directly the PSD falls roughly into this range.  
However, a slightly different strategy must be employed when measuring the PSD of 
droplets in a dynamically changing plume, and in our case we are mostly concerned with 
the large droplets, which carry the majority of the payload of the medicine.  For reference 
a single 10 μm droplet can carry one thousand times more mass than a 1 μm droplet.  
Furthermore, it is known that upon forming a vortex some droplets can be ejected from 
the core filament dependent upon their size, density and the viscosity of the gaseous 
media (23).  This could potentially cause a size segregation of the droplets spatially 
within the vortex and as the toroid propagates.  Thus, it is important to note where the 
payload of the dose is located in relation to the vortex geometry because this could 
influence the amount of drug available for deposition onto the surface. 
In order to assess this we utilized laser diffraction with ultra high speed time 
slicing (0.5 ms time base).  This allows for the determination of the PSD of the droplets 
spatially within the toroidal vortex including: A) the leading edge of the vortex, B) the 
center point when the toroid is completely within the beam, and C.) at the trailing edge of 
the vortex.  These special cases are illustrated in following figures respectively: A: Figure 
4.7, B: Figure 4.8, C: Figure 4.9).  Furthermore, the optical concentration was also 
measured simultaneously in order to assess the onset of the vortex entering the laser.  A 
time resolved plot of optical concentration (Copt) and the X90 droplet size is plotted in 
Figure 4.10, (Labels A ,B & C correspond to regions of the toroid previously 
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mentioned.).  Because the vortices are highly symmetrical, the leading edge of the vortex 
is representative of the outer edge or shell of the toroid.  In the laser diffraction data plot 
in Figure 4.10, it can be seen that as the toroid moves through the beam path, there is a 
decrease in droplet size and as the toroid leaves the beam, the droplet size increases 
again.  More specifically, in this example the leading edge of the toroid, Labeled A, has 
an X90 of 5.75 µm, while in the center it drops down to 5.15 µm, and then as it exits the 
size increases to 6.58 µm.  This differential in size could be due to the aforementioned 
effect where droplets can be segregated in vortical flows based off their size and the 
relative velocity of gas in which they are entrained.  Furthermore, it appears that the 
larger droplets are ejected from the core due to inertia, and occupy the out shell of the 
vortex, while the smaller droplets either remain in the core or drift inward due to the drop 
in relative pressure caused by the vortex.  However, it should be mention that it is also 
possible that due to the increased number of droplets that are present when at the peak 
optical concentration, multiple light scattering events could be contributing to this 
observed change.  Multiple light scattering cannot be ruled out completely but it is 
unlikely as our measurements took place below the recommended limit for Optical 
concentration of 15% outlined in USP<429>.  Nonetheless, it can be seen directly that the 
PSD of the droplets are not changed to the scale that would affect their deposition and 
thus their performance for ophthalmic applications.  
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Figure 4.7.  Front Edge of a Toroidal Vortex Entering the Laser Diffraction Beam 
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Figure 4.8.  Toroidal Vortex is Entirely Inside Laser Diffraction Beam 
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Figure 4.9.  Back Edge of a Toroidal Vortex Illuminated by the Laser Diffraction Beam 
as it Exist the Beam Path 
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Figure 4.10.  Optical Concentration plotted (solid circles), and Droplet size X90 (µm) 
(solid triangles) plotted as a function of Time.  Label A.) indicates the front 
edge of the Toroidal Vortex. B.) When the Toroid is entirely in the laser 
beam path. and C.) The back/outside edge of the Toroid 
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Another feature that is noticeable when looking at the optical concentration-time 
curve from Figure 4.10, it can be seen that the signal does not return to the baseline.  This 
is due to the lingering tail that exists during the early stage of vortex formation.  These 
are droplets that are too large or too far away from the entrainable fluid flow to be 
captured into the vortex, and thus forms a streak as the vortex propagates.  This streaking 
is also visible in the high speed video frames (Figure 4.11).  Finally, from the data point 
at Label C)  it can also be seen that the size of the droplets in the tail are larger than core, 
and more comparable to that of the front edge of the vortex, further supporting the notion 
that the radially centered portion of the vortex does in fact contain the smaller droplets 
(23).   
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Figure 4.11. Cross-sectional View of a Toroidal Vortex Propagating at 5,000 frames per 
second 
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Toroidal Vortex Propagation Dynamics 
 
Another critical aspect of the device is the ability to deliver the aerosol at an 
effective, safe and comfortable speed.  A high level balance between droplet velocity and 
impaction force is required here, because the aerosol needs to be moving fast enough to 
impart adequate inertial characteristics onto the droplets so they can be deposited 
effectively on the eye surface without being intercepted by a possible blink reflex, while 
still being gentle enough to not cause discomfort.   
The propagation of the toroidal vortex can be broken into two main components: 
(1) the bulk velocity of the vortex ring as whole (translational) and (2) the net or max 
droplet velocity within the vortex (rotational velocity plus translational).  The bulk 
velocity of the plume was measured by tracking the front edge of the toroid; this provides 
information as to how of how long it will take for the vortex to reach the eye at a set 
distance.  In addition, because the vortex velocity was tracked at a distance we can 
determine the optimal spacing from the nozzle and account for any deceleration if the 
eye-piece spacer needs to be adjusted.  
Previous studies had shown that the velocity of an emitted vortex was 
proportional to the actuation force, however that velocity data was produced using a 
calibrated pendulum which is not feasible for patient use (16).  An electronic actuator 
was built to impart the forces required to generate the toroidal vortices, and the control 
was modulated with a variable voltage supply.  The device was then actuated at a low, 
medium and max voltage to obtain a velocity profile for each actuation energy as well as 
for each device over the distance relevant for delivery to the eye (~3 cm).  The bulk 
velocity was from EZ device is displayed in Figure 4.12, and the OMR device bulk 
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velocity is shown in Figure 4.13.  These figures, show that bulk velocities are quite 
reproducible and only slightly decrease over the distances measured.  Furthermore, it can 
be clearly seen that there is a noticeable difference in the bulk velocity of toroids for each 
level of actuation energy, and also between devices.  The EZ Device has a nearly double 
bulk velocity at each actuation energy than that of the OMR Device. We attribute this 
difference in velocity to the nature of the venting on the aerosol generator.  Because the 
chamber is relatively sealed when force is applied to the actuating membrane, the 
pressure inside the chamber is momentarily built up.  In the case of the OMR device, 
designed venting from within the device allows for this pressure build up to dissipate 
more readily, therefore reducing the amount of energy that is directed toward ejecting the 
toroidal vortex.  Nonetheless, despite the geometric differences and internal venting 
dissimilarities in the aerosol generators, each of the devices produced very reproducible 
velocity profiles.  Furthermore, for each of the devices, the velocities only dropped by 
approximately 10% from the nozzle to a distance of about 25 mm, where they would 
likely impact eye.  This will be useful information for determining the optimal distance to 
set the orifice relative the eye for administration. 
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Figure 4.12.  Bulk Velocity of Toroids Generated from the EZ-Atomizer Equipped 
Device, as a function of Distance from Device Orifice. 
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Figure 4.13.  Bulk Velocity of Toroids Generated from the Omron Equipped Device, as a 
function of Distance from Device Orifice. 
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Overall, we found that in all of the cases, even the slowest moving toroid from the 
slowest device (OMR- at 6 volts), and the amount of time it would take to deposit, is on 
the order of 30 ms from actuation to contact.  This is clinically relevant because the 
amount of time it takes for the human blink reflex is nearly 300 ms.  This means that 
even if the actuation of the device causes a reflex blink, the toroid would have already 
exited the device and impacted the eye before the eye-lid could close and block the dose. 
However, these findings do not rule out the possibility of the patient having an 
anticipatory blink or “normal blink” which starts from before the device is actuated.  
Beyond testing the bulk velocity of the toroids, because they are rapidly 
circulating it is also important to determine the maximal velocity of the droplets within 
the toroidal vortex.  This takes into account the bulk velocity plus the rotational velocity.  
This velocity has major implications in terms of assessing inertial deposition and net 
impact force onto the eye.  As can be visualized in the 2D-Velocity Contour plots in 
Figure 4.14, the internal core of the vortex is where the maximal velocity is located. This 
is because as the vortex propagates the outer walls are rotating around a circular central 
axis and as it rotates around towards the center of the ring, this rotational velocity is 
added to the net velocity of the droplets (indicated by the blue region of the 2D velocity 
contour plot). The opposite is the case on the outside edges of the toroid, where the 
droplets are actually moving in the opposite direction of toroid propagation (indicated by 
the red region on the 2D velocity contour plot). This contrasting velocity field has an 
interesting effect on the performance, because at low bulk (translational) speeds, the 
rotational velocity is high enough to cause a net relative velocity in the opposite direction 
on the outside walls. The outside edges of the toroid in (FIG>Contour plot EZ-6V) 
indicate a net negative velocity of the droplets. This is important because these droplets 
will not be available for deposition onto the surface because they will not have forward 
 131
inertia and they can be effectively subtracted from the available surface area of 
impaction.  However, this net negative effect on the outer edges is eliminated at higher 
toroid velocities, thus increasing the effective impact surface area. In this case, the total 
forward moving velocity overcomes the rotational velocity and thus the entire toroidal 
surface area then becomes available for deposition, which can help to explain the 
observed higher dose deposition which occurred at higher speeds that was reported 
previously (16). 
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Figure 4.14.  Stereoscopic Particle Image Velocimetry- 2D Contour Plots for Droplet 
Velocity Vectors. 
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In summary each of the devices tested showed a high level of precision and 
reproducibly when generating aerosol plumes over a range of velocities.  Moreover, The 
EZ device (Figure 4.15), and the OMR device (Figure 4.16) exhibited nearly linear 
increase in bulk toroid and maximum droplet velocities across all of the actuation 
energies.  This level of consistency and predictability will offer a higher degree of control 
when applying aerosol the surface of the eye.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 134
 
 
 
 
 
 
 
Figure 4.15.  Comparison between Toroid Velocity Maximal Drop Velocity at Different 
Actuation Energies for EZ-Atomizer Device 
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Figure 4.16  Comparison between Toroid Velocity Maximal Drop Velocity at Different 
Actuation Energies for OMR Device 
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 Special Considerations regarding Uncertainty and assumptions: 
During the course of making PIV measurements and collecting data, uncertainty 
can arise in two main ways with PIV measurements.  The first uncertainty pertains to the 
velocity magnitudes, and it is estimated that based on the correlation statistics approach 
(Wieneke, 2014) that for all cases it is found to be less than 0.04 m/s and 0.1 m/s for the 
in-plane and out-of-plane motion velocity components (24). The second aspect of 
uncertainty relates to the position of the laser sheet relative to the toroidal vortex.  
Because the goal of the experiment is to measure the velocity in a centerline cut plane in 
which the vortex travels, it is imperative that the orifice is properly aligned.  However, a 
misalignment may still exist either from the onset or via drift as the vortex propagates. In 
order to correctly interpret the measured velocities the stereoscopic PIV was employed.  
The alignment of the cameras is able to detect and obtain data from the out-of-plane 
velocity field.  
 
Differences in Aerosol Generating Devices 
In these experiments we used two different aerosol generating devices and 
attached them to the vortex drug delivery device.  Both of the aerosol generators operate 
via the same aerosol production mechanism (i.e vibrating mesh technology), but they 
have different specifications.  Because they typically produce aerosols with similar size 
characteristics, any small differences in droplet size between the devices would not likely 
have an effect on the velocity data. 
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Relative Impaction Force 
During the toroidal vortex velocity and PSD testing we concluded the EZ-
Breathe-AG equipped device provided the widest range of velocities as well as an 
adequate PSD for evaluation in the relative impact force screening.  This method was 
developed in house to provide only in a relative sense the forces these toroidal vortices 
may impart onto a surface.  Delving into the complexities of the impaction onto an actual 
ocular surface is beyond the scope of this manuscript.  However, this analysis can provide 
guidance into evaluating the nature of the impaction and help to reduce concerns one may 
have about the comfort of the administration.  
When deciding which device and loading scheme to evaluate for this method we 
had to consider the very small magnitude of the forces we were attempting to measure.  
Initial testing of the device without loading aerosol was found to be below the limit of 
detection of the microbalance.  Previously Guo et al. investigated impaction forces 
generated from nasal sprays and pressurized metered dose inhalers using a TA 
Instruments texture analyzer which was turned onto its side and the doses were impacted 
onto the probe detector (25), however, the forces in consideration in this study were 
found to be much lower in magnitude than this instrument would allow. Furthermore, 
Muller et al. investigated the impaction force generated by ophthalmic sprays using a 
piezoelectric transducer at several distances.  In addition, Muller et al. has also developed 
techniques for measuring impaction force but still none of these methods are sensitive 
enough to detect on the micro-Newton scale(<1  mg-F) (25-27).  
The principles of force measurement between our experimental set-up and others 
is nearly identical however the piezo-electric transducer within the analytical 
microbalance is much more sensitive and allowed to data streamed so that a peak force 
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could be obtained.  Upon actuating the device at a distance of 3 cm at low voltage only a 
small deflection in baseline force was measured, on the order of about 0.3mg.  This was 
determined to be about as low as our balance would allow reproducibly.  As the actuation 
voltage was increased the impact force was only slightly altered, until the maximal 
actuation force of 12 V relayed a deflection of 0.5 mg, which correlates to about 4.5 
micro-newtons.  The microbalance was capable of reproducibly measuring these force 
curves, and a typical force-time curve is reported in Figure 4.17.  Figure 4.18 shows the 
relationship between actuation force and impact force.  It was demonstrated that even at 
the highest actuation energy, there was only a very small increase in relative impact 
force. 
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Figure 4.17.  Typical Peak Relative-Force curve. 
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Figure 4.18.  Actuation force vs Relative Impact Force 
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Previously Muller et al. showed that when comparing an eye drop to an eye spray, 
there was an inverse relationship between the distance of application and the force for the 
spray and a direct relationship between impact force for drops and distance.  In essence 
the drops gain momentum and impact harder the further they are away, while the spray 
loses velocity the further away it administered.  While this decrease in impact force from 
distance is preferable, a drawback with spray type devices is that they emit aerosol in a 
cone-type geometry, meaning that the further away from the device the larger the 
diameter of the cone.  Muller et al. found that at just a distance of 1 cm the diameter of 
the cone was ~25 mm, not only is this larger than the diameter of the exposed portion of 
the eye, this distance corresponds to impact force of about 10 mN.  This impact force 
corresponds to about a 1 gram-force, nearly 2,000 times the forces generated from the 
toroids found in our studies and triple the force created by an eye drop at the same 
distance.  At an equivocal distance of 3 cm, the spray force from a spray is reduced ~5 
milli-N, but at the cost of increasing the diameter of the spray cone to about 35 mm, 
where a large portion of the spray is likely to miss the ocular surface.  
Uncertainty in these measurements exists in the orientation of the device in that if 
the toroidal vortex does not directly impact the plate the results will be slightly different.  
In addition, if the vortex hits off center the pan this will cause a competing torque force 
on the lever arm.  These results will be untrue to the method.  Nonetheless, for the 
purpose of demonstrating the relative scale (semi-quantitative analysis) of the impaction 
forces as they pertain to the clinical relevance of this device this method was 
demonstrated to be satisfactory.   
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CONCLUSIONS: 
 
In summary, we found that despite the large differences in velocity both bulk and 
maximal droplet velocity the resulting impact forces generated from these toroidal 
vortices changes very little and this likely due the small mass contained in each vortex.  
Furthermore, it was determined this impact force is far below the threshold for what a 
patient could tolerate relative to other forces currently used clinically in patients.  In 
addition we also measured the size of the droplets to be on the order of which would be 
suitable and comfortable for ocular drug delivery and that the delivery of the bolus would 
likely out-pace reflex blinking if it were to be triggered by the device.  These preliminary 
studies have offered support for advancing the investigation into a pre-clinical setting and 
much more testing would need to be conducted to show the performance, safety and 
efficacy of the delivery device in animal and human subjects.  
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SECTION 3: FORMULATION STRATEGIES 
Chapter 5 :  Solubilizing Agents for Improving Drug Loading into 
Aerosolized Ophthalmic Toroidal Vortices 
 
ABSTRACT 
Recently there has been an increased interest in the use of liquid aerosols to 
deliver medicine to the surface of the eye particularly due to their small volume 
capabilities.  We have developed and previously described a precision aerosol device for 
ocular delivery.  In this article we investigate the use of two different excipients, 
hydroxypropyl-β-cyclodextrin and glycerin, for use as solubilizing agents and for 
modifying the rheology for use in an ocular aerosol formulation.  We found that while 
both excipients contributed a comparable amount to the dynamic viscosity of the 
formulations by weight, they had dramatically different ability to solubilize the active 
ingredient, diclofenac sodium.  Furthermore, HPBCD negatively affected the aerosol 
output rate but not to an extent that overcame the higher solubilization capacity benefits.  
Finally we found that neither of the vehicles significantly altered the droplet size 
distribution across a wide range of concentrations. 
 
INTRODUCTION 
 
Recently there has been an increase in the prevalence in ocular related disorders 
and this only expected to increase with an aging population.  As of 2013, there was an 
estimated 64.3 million patients affected by glaucoma, which is expected to increase to 76 
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million by 2020, and even to over 110 million by 2040 (1).  This new era of medicine 
requires new outside the box thinking in order to solve some of these long-standing 
problems with ophthalmic treatments.  While there have been major developments in 
creating new drug entities to treat various ophthalmic conditions there still remains major 
barriers to getting the medication to the target tissues.  Using conventional dosage forms 
such as eye-drops, it is estimated that less than 5% of administered medication makes it 
to the target tissues, and in some cases less than 1% (2-4).  Other problems associated 
with eye drop include poor patient compliance, ease of use and unfavorable systemic side 
effects (5, 6).  
The biological challenges associated with topical ocular drug delivery mostly 
depend on either penetrating the physical barriers such as the cornea, sclera and uvea. But 
also in overcoming the physiological aspects of the ocular system such as tear 
production/rinsing of the surface with enzymes that degrade drug molecules before 
permeating the ocular membranes.  Without modifying the chemical active (as in the case 
of prodrugs) scientists are limited to the addition of excipients and altering the dosage 
forms.  The main strategy for increasing the bioavailability is to increase the permeation 
of the drug or the residence.  To increase the permeation of the drug scientists have used 
several techniques such as, permeation enhancers which can alter the membrane barrier 
to promote absorption.  Also scientists can increase the concentration gradient, within the 
tolerable limits of the eye to promote diffusion.  Another strategy to increase to 
bioavailability is the targeted use of transporters to either increase the drug influx or 
reduce/block the efflux across key barriers (7). 
Aside from altering the dosage form to improve permeability, scientists have also 
made attempts to increase the residence time at the surface of the eye in order to increase 
the extent of absorption.  Some of these strategies include increasing the viscosity of the 
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instilled liquid, as in the case of in-situ forming gels or ointments.  Blurring vision and 
difficulties in application may limit widespread use of this approach.  The use of drug 
loaded ocular inserts, contact lenses, punctal plugs etc. can also greatly improve the 
residence time at the interface of the eye.  However, issues with administration and 
ejection also pose a challenge with these systems in their current design.  
As early as the 1970’s scientist learned that instilling eye-drops in small volumes 
could reduce clearance from the surface of the eye and increase the bioavailability and 
further reduce the systemic effects (8, 9). It was only a few years later when scientist 
began incorporating these small drops into sprays or mists to deliver the liquids to the 
eye(10, 11) . While they were demonstrated to be equivalent in many cases despite a 
smaller delivered dose, this technique did not catch on due to variability in the plume 
spray and in ability to direct it onto the eye and not the surrounding tissues.  More 
recently, companies such as Mystic Pharmaceuticals and Eyenovia have developed 
devices to administer sprays onto the eye in a more controlled manner. 
As mentioned previously, the formulation of aerosols for topical administration to 
the eye has a separate set of limitations as to that of typical eye-drops or solutions for 
inhalation.  When depositing aerosols (micronized droplets) onto the eye, a very small 
volume of liquid is actually instilled.  Therefore this requires a much higher concentration 
of active ingredient at least 10X what is typically used in eye drops.  This high 
concentration of solubilizing agent can work synergistically by increasing the viscosity of 
the liquid to promote retention on the ocular surface.  However, this increase in 
concentration can alter the physicochemical properties of the liquid such that the 
aerosolized medication is compromised.  Therefore we must determine the optimal 
concentration of cyclodextrin or glycerin that will allow for maximal dosing without 
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reducing the aerosol output from the aerosol generator and shifting the droplet size 
outside of a usable range.  
Early research by several groups showed that the drug permeability across the 
corneal membrane could be directly increased by loading the drug into cyclodextrin 
complexes and by possibly altering the structure of the corneal epithelia (12-14).  
Cyclodextrins are cyclical oligosaccharides that have different hydrophilic functional 
groups exposed on the outside surface and lipophilic groups in the core on the inside, 
where a lipophilic drug can be solubilized.  The cyclodextrin complexes work in two 
main ways.  Firstly, they increase the solubility of the drug in the aqueous phase thereby 
increasing the availability of the drug at the membrane for diffusion.  And secondly, they 
are reported in some cases to alter some membrane constituents and thus change the 
permeation characteristics of the membrane(15).  In the case of solubilizing lipophilic 
drugs, the solubilized drug or uncomplexed drug can diffuse more readily across the 
membrane (16). This solubilization technique is widely used in other drug delivery 
methods/routes as well as in investigational ophthalmic applications, and cyclodextrins 
are used as the main solubilizer in the Voltaren® Optha eye drop formulations already 
approved for use in the European Union (17). 
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MATERIALS AND METHODS: 
Materials: 
 
Phosphate buffered saline was purchased from Sigma-Aldrich. Hydroxypropyl β-
cyclodextrin (Cavasol® W-7 HP) was graciously donated by Wacker Chemie AG.  
Glycerin and Sodium Diclofenac (DCN) were purchased from Fisher Scientific.  De-
ionized water (in house).  Finally, an Omron MicroAir Vibrating mesh nebulizer, which 
was generously donated from Omron Healthcare Inc.(Wake Forest, IL) 
 
Methods: 
 
Cyclodextrin complexation and aqueous cosolvent formulations were prepared by 
shake-flask phase solubility methods set forth by Higuchi and Conners (18). Each 
formulation was set on shaker and equilibrated for 24 Hrs and filtered through a 0.2 um 
PTFE syring filter prior to analysis.  To determine the amount of diclofenac sodium 
solubilized by HPBCD the samples or the co-solvent system, placebo formulations were 
used as blank with the corresponding formulation and diclofenac loading was quantified 
by UV-Vis spectroscopy using a Tecan M200 spectrophotometer, measuring absorbance 
at a wavelength of the 276 nm. 
 
Output Rate: 
The nebulizer output rate/aerosol generation rate was determined gravimetrically 
in triplicate for 5 second intervals of time for each formulation.  In addition the 
supplementary measurement of optical concentration was done using the laser diffraction 
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apparatus to give an indirect measurement for droplet concentration which could indicate 
nebulizer output rate. 
 
Droplet Sizing: 
Particles/Droplet Size was measured using a Sympatec Helos Laser Diffraction 
Apparatus with the open bench set up. The LC 15mm focal length lense was used at set 
distance of 100mm.  The particle size distribution by volume was calculated using HRLD 
and the key outputs from the report form are X10, X50 and X90.  Finally, the optical 
concentration was also measured simultaneously as an indirect means for correlating 
droplet concentration to the nebulizer output rate. 
 
Kinematic Viscosity: 
The kinematic viscosity of each of the formulations (n=3) was measured using a 
Cannon-Fenske, glass capillary flow through viscometer equilibrated at RT for 30 
minutes prior to measurement. 
 
Complexation Constant: K1:1 
To determine the binding affinity between the diclofenac and the HPBCD, the 
solubilization capacity was plotted vs the molar amount of cyclodextrins.  The formula 
for the complexation constant K1:1, is given by Equation 1, below(19).  Where the slope, 
is the slope of the plot for solubilized diclofenac Na vs Molar Concentration of HPBCD.  
And D0, is the baseline equilibrium solubility for diclofenac Na. 
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Equation 1: 
K1: 1 ൌ ݈ܵ݋݌݁ܦ0ሺ1 െ ݈ܵ݋݌݁ሻ 
 
 
Preparation of the Solubilized Formulations: 
 
Cyclodextrins have widely been studied for use in the eye as solubilizers, 
penetration enhancers, stabilizers and are approved for use in eye drops in Europe (20, 
21). While they have been formulated for use in eye drops, this is the first of our 
knowledge where highly concentrated solutions have been nebulized into micro-droplets 
for ocular use.  When formulating aerosols for ophthalmic drug delivery a different set of 
concerns need to be taken into consideration, as the nature of the delivery of the 
microdroplets is slightly different.  The main difference is that the total volume of liquid 
that is being added to the tear film is dramatically reduced from about ~50 µl to less than 
1 µl.  This has ramifications because the there is a physical limit to how much drug can 
be loaded into this very small volume and in this case we are attempting to maximize the 
dosing so that at a later time if need be the dosing can be reduced.  The limits of the drug 
solubility ultimate dictate how much drug can be incorporated into the droplets.  On the 
other hand a couple of the normally limiting aspects of drops can also be avoided.  A 
table (Table 5-1) of the relevant physicochemical properties is shown below.  
In this very specific case, because of the very small instillation volume, it 
necessitates that the solution is much more concentrated than a typical eye drop.  And 
because diclofenac has limited solubility in aqueous solutions, higher amounts of 
solubilizing agent must be incorporated in order to achieve adequate dosing. 
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Balancing the incorporation of a poorly water soluble drug into a formulation 
which is still capable of being aerosolized with the desired characteristics is a challenging 
task, especially at higher concentrations of solubilizer.  A normal eye-drop formulation is 
not held to these limitations but the normal eye-drop also does not have very stellar 
performance either, sometimes <1% bioavailability. 
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Table 5-1.  Physicochemical properties of Key Formulation Components 
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Complexation Binding Constant: 
The ability of a cyclodextrin to solubilize a drug molecule depends largely on the 
geometry of the molecule and physicochemical characteristics of the drug.  In this, 
Diclofenac Na, has pH dependent solubility but is not soluble enough for the high 
concentrations needed in aerosol delivery.  It also has a high log P, which makes it a good 
candidate for solubilizing with cyclodextrins, because the core of the HPBCD is 
hydrophobic.  When formulating with cyclodextrins it is important measure the binding 
coefficient for the complex.  The binding coefficient mathematically describes how 
tightly the drug molecule is incorporated into the complex.  While high binding 
coefficients mean high solubilizing capacity they also indicate that drug may be too 
tightly bound to the complex to be liberated for absorption.  On the other hand very low 
binding coefficients correlate with very low solubilizing capacity and typically, high 
amounts of excipient are required to in order to achieve adequate concentrations.  
Diclofenac Na was found to have a K1:1 of ~105 which is in the feasible range outlined by 
Rao et al.. See Figure 5.1., below, to observe the linear relationship between CD 
concentration and solubilized DCN.  Others have investigated the use of cyclodextrins 
with diclofenac in ophthalmic applications (22, 23).  However, in these experiments the 
required target concentrations to be delivered are much higher than those previously 
attempted to apply in eye drops because this delivery method deposits the drug in very 
small volumes of liquid. (For reference the commercial Voltaren® eye drops are only 
0.1%)  
Increasing the solubilizing agent improves the solubility and thus the loading into 
the aerosol droplets however there is a trade off on quality of the aerosol produced at 
some point the output rate is compromised so that in the same amount of time (chamber 
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fill time) less actual drug is processed into droplets therefore reducing the net payload of 
the device. 
 
 
 
 
 
Figure 5.1.  Phase Solubility Plot of Diclofenac Sodium in HPBCD 
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Advantages Over Eye Drops: 
For one, when adding very concentrated, small volumes of liquid to the small 
volume of the existing tear film, theoretically, there is not a large change in volume to 
stimulate tear production, so the dilution of tear film over time can be minimized.  In the 
case of an eye-drop instillation, the pre-corneal space is over-filled, and the entire tear 
film is virtually replaced with the eye-drop.  And because the surface of the eye is very 
sensitive to changes in fluid volume and temperature, as well as the osmolarity and pH, 
the incoming formulation must be precisely balanced.  Otherwise, tears will be rapidly 
secreted in order to re-establish equilibrium, thus washing away the dose from the ocular 
surface.  In micro-droplet delivery we are essentially depositing the solubilized drug 
material and a few excipients directly into the existing tear film, thereby minimizing the 
role of osmotic agents and pH modifiers.  Furthermore, the use of preservatives in normal 
eye-drop formulations has been an emerging problem for use in chronic therapies since 
we have learned of their corneal toxicities.  When using microdroplets, the concentration 
of the preservative can be used the same concentration used to preserve liquids at room 
temp; however, the actual exposure to the patient is dramatically reduced due to the lower 
overall volume of liquid administered to the patient. 
 
Kinematic Viscosity: 
 
The major physicochemical property that affects the ability for these 
pharmaceutical solutions to flow is the kinematic viscosity.  While the degree which the 
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effects of viscosity on performance are highly dependent on the aerosol generator 
mechanism, there exists an upper limit in which these liquids will no long flow freely and 
become nearly impossible to aerosol regardless of the mechanism.  In vibrating mesh 
aerosol generators it is crucial for the fluid to be able flow through the micro-drilled holes 
that create the mesh.  The literature suggests that the range of droplets capable of being 
produced is bound by the size of the holes in the mesh (24). However, interactions 
between the micro-orifices and liquids with different physicochemical properties can 
yield slightly different droplet size distributions and ultimately alter the rate at which 
droplets can be generated (24-26).  In both cases with increasing concentration of 
solubilizer there was increased viscosity but HPBCD showed the highest increase at the 
upper loading concentration.  A comparison of the kinematic viscosities of the vehicles at 
different concentrations is shown below in Figure 5.2.  Furthermore, when incorporating 
DCN, this did not have an effect on the kinematic viscosity beyond that of the vehicle 
alone (Figure 5.3) 
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Figure 5.2.  Plot Showing Kinematic Viscosity Increases as Vehicle Concentration 
Increases 
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Figure 5.3.  Kinematic Viscosity of Top Solubilizer Formulations 
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Droplet Size Distribution: 
 
We found that despite large changes in formulation composition the droplet size 
distributions for each of the formulations almost had no effect.  A summary of the droplet 
size distribution characteristics is displayed in Table 5-2.  Others have reported small 
changes in PSD for different physical chemical properties of the solutions, however 
others have also reported on the robustness of the performances of the vibrating mesh 
technology (25).  Having reproducible droplet size from this ophthalmic aerosol device is 
crucial as the momentum of the droplets directly related to their diameter (e.g. mass) and 
velocity.  In addition, maintaining a consistent droplet size distribution is important 
because the overall payload of the dose is heavily dependent on size and number of the 
droplets and the more consistent and reproducible, the better to the delivered dose 
uniformity and ultimately the reliability of the delivery technique.  
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Table 5-2.  Droplet/Particle Size Distribution and Optical Concentration Data for Each 
Solubilizer Formulation. 
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Nebulizer Output Rate: 
One of the main ways the dosing of this device is tuned is via the chamber fill 
time.  Increasing the mass of aerosol (i.e. # of droplets) into the chamber has very 
predictable and reproducible effect on drug deposition after being emitted from the 
device.  So in this regard, the nebulizer output rate directly influences the amount of time 
needed to adequately fill the device aerosol chamber prior to actuation.  We found that 
the amount of solubilizing agent used had a smaller effect on the aerosol output rate than 
just the neat addition of the drug to the phosphate buffered saline solution (compare 
Figure 5.4 (solubilizers alone) to that of Figure 5.5 (solubilizers plus DCN ).  The normal 
output rate for PBS was ~5 mg/sec, and adding the diclofenac to the formulation at a 
concentration of 0.1% (w/v), reduced the aerosol output down to about 1.2 mg/sec but 
further increasing the concentration to 0.5% only did not noticeable affect beyond the 
initial drop.  This effect could possibly be explained by the surface active properties of 
diclofenac, and its interaction with the vibrating mesh (27, 28).  Futhermore, compared to 
the vehicle solutions without diclofenac, the incremental addition of glycerin increased 
the kinematic viscosity, but the output was only slightly reduced.  Cyclodextrin showed 
an intermediate reduction in aerosol output rate compared to that of glycerin and 
diclofenac.  A 5% CD solution had nearly the same output rate as just a 0.1% DCN in 
PBS.  Ultimately, with increased concentration of cyclodextrin to 20%, there was a point 
when the output rate was brought to an absolute halt.  With glycerin, the rate was 
drastically slowed, from 5 mg/sec to 3 mg/sec at 20% w/v, but we did not investigate 
beyond the concentrations necessary for solubilization (Figure 5.4).   
In order to establish the most optimized formulation, the solubilization capacity 
and the effects on output rate must be considered.  Glycerin as a cosolvent had a very 
small effect on output rate, but was an inferior solubilizer to HPBCD.  And on the other 
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hand HPBCD, was a great solubilizer, but negatively affected the output rate.  Herein 
lays the compromise, because the higher loaded solubilities (e.g. 20 CD%) were able to 
encapsulate much more drug per droplet (i.e higher payload).  But this was at the expense 
of the aerosol generation rate (Figure 5.5).  Therefore at a set chamber fill time of 3 
seconds, there would theoretically be a reduced amount of drug dispersed.  Because of 
the reduction in output rate at the high CD concentrations, the high drug payload would 
most likely come from the 1% DCN-1% HPBCD formulation with a 3 sec chamber fill 
time, because the much higher output rate over compensates for the reduced 
solubilization as is shown in Figure 5.6,  by a net increase in DCN generation over time. 
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Figure 5.4.  Effects of HPβCD and Glycerin Conentration on Aerosol Output Rate 
 
 
 
 
 
 
 
 
 167
 
 
 
 
 
 
 
 
 
 
Figure 5.5.  Aerosol Output Rate with Diclofenac and Vehicles Combined 
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Figure 5.6.  Effect of Solubilization Capacity and Output Rate Dictates Maximal Dose 
Generation Rate.  
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CONCLUSIONS: 
These experiments have been shown to be crucial for the optimization of dosing 
from this advanced type aerosol delivery system, in that the toroidal vortex dynamics can 
be physically modulated with the device but the nature of the aerosol being emitted must 
also be optimized by formulation strategies in advance.  Unique challenges are created 
when attempting to delivery very small volumes of a solution to the ocular surface. 
Particularly when working with poorly water-soluble drugs or compounds that cannot be 
formulated at pH in which they are more soluble.  And when incorporating solubilizing 
excipients into aqueous based systems for nebulization special care is needed to ensure 
that the physic-chemical properties of the solution are not altered to much that 
characteristics of the generated aerosol are compromise.  We found that despite large 
changes in the viscosity of the solution formulations, it did not have meaningful effect on 
the droplet size distribution.  Furthermore this increased viscosity did have a net negative 
effect on the nebulizer output rate, demonstrating that there is an upper limit to how much 
solubilizer can be incorporated and sill form adequate aerosols. This also translates to an 
up limited of drug solubilization and how much drug can be incorporated into droplets. 
Finally, a clear trade off exists in the solubilization capacity of the solution, and the 
aerosol generation rate.  Caution must be observed, as high droplet loading may come at 
the cost of generating much less aerosol, and thus the drug payload.  While the effects of 
the vehicle on aerosol performance were clearly demonstrated here, it is important to re-
evaluate the performance when attempting to solubilize other drug molecules because 
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they will have different physicochemical properties and thus could perform as a vastly 
different system.   
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Chapter 6 :  Super-Heated Aqueous Particle Engineering (SHAPE): A 
Novel Method for the Micronization of Poorly Water Soluble Drugs 
 
ABSTRACT 
Super-heated aqueous particle engineering (SHAPE) is a novel particle 
engineering technology that utilizes the elevated boiling point of pressurized water in 
order to melt and emulsify hydrophobic drug particles, and then use the newly formed 
droplets as templates for engineering new particles with different physicochemical 
properties.  When the temperature of an aqueous phase is elevated above the melting 
point of a drug, the drug quickly melts and forms a low viscosity, immiscible liquid, 
which is then broken up into nano or micro sized droplets under continuous stirring.  The 
interfacial tension between the droplets and liquid serves to shape them into uniform 
spherical particles.  These droplets can hold their shape as the dispersion is cooled back 
down below the melting point of the drug.  During this cooling stage, either solid 
crystalline or amorphous microparticles can be formed depending on the cooling rate that 
is selected.  The particles are then collected and can be utilized in many different 
pharmaceutical applications.  In this manuscript we use this particle engineering 
technique, employing the model drug carvedilol, to investigate the effect that different 
stabilizers/surfactants exert on the particle size and morphology. 
 
INTRODUCTION 
Particle engineering in the pharmaceutical industry has become an essential tool 
for the fine-tuning and performance of pharmaceutical products, with broad applications.  
The range of purposes for particle engineering is quite broad and encompasses everything 
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from reducing particle size, to improving dissolution and enhancing absorption, all the 
way to producing stabilized particles with optimal characteristics for various routes of 
administration.  Despite the broad utility of particle engineering, the main goal in every 
situation is to alter the physicochemical characteristics of a raw material in order to 
overcome the barriers or problems that occur with the:  manufacturing, stability, 
performance, and efficacy of the drug product.  
The overwhelming majority of particle engineering technologies come from either 
of two different classifications, the top-down approach or the bottom-up approach, each 
having differences in advantages and disadvantages.  The top-down approach utilizes 
mechanical energy and/or shear to break apart particles into smaller, more uniform 
particles.  Oppositely, the bottom-up approach uses a solvent or mixtures of solvents to 
precipitate particles from a solution.  It should also be mentioned that there are also 
combination techniques, which use precipitation and milling/grinding or homogenization 
in conjunction in order to achieve the proper particulate product characteristics, such as 
the NANOEDGE™ and smartCrystal® technologies (1).  In general, top-down 
approaches are time consuming, requiring many long milling steps, and there have been 
reports of contamination of the final product with fragments of the milling media.  In 
addition, high energy milling can impart amorphous characteristics onto the surface of 
the particles.  This may have negative effects on the stability and/or performance of the 
final drug product.  The major drawback for bottom-up approaches is that these methods 
require that the engineered material be adequately soluble in a particular solvent (or 
solvent system), and must be able to be precipitated with another.  This may not always 
be achievable with appropriate pharmaceutical solvents.  Furthermore, many of these 
solvents are toxic and processing materials with them requires additional purification 
steps.  The use of many of these solvents also increases safety risks during 
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manufacturing, which, in turn, increases production costs and raises additional 
environmental concerns. 
We introduce herein a new, solvent-free approach, which utilizes thermal energy 
to create a molten-templated intermediate step, for the formation of uniform particles.  
This technique can be described as being a hybrid of the two main approaches previously 
mentioned, as this novel approach uses mechanical energy to disrupt and break-up 
droplets, but a melting step allows for the disruption of the original crystalline structure, 
which is reformed upon controlled cooling.  This reformation of the crystal form offers 
an additional potential benefit for this processing technology, in that, by altering the 
cooling or heating profile one can potentially alter and/or select for different polymorphic 
forms of the active pharmaceutical ingredient (API) (2).  The selection of the 
polymorphic form of pharmaceutical actives is essential as they can have largely different 
physicochemical properties (3).  According to Lee et al, and Ostwald’s rule of stages, 
melting and cooling profiles can be altered to select or screen polymorphs with different 
stabilities as the molecules are able to transition between forms depending on their 
energy (4).  Although polymorphs can be selected and screened by precipitation 
processes and other methods, the SHAPE technique offers an all-in-one approach for the 
production of fine, monodisperse particles, with a potential opportunity to selectively 
alter their polymorphic form as required by the API and application.  
In this article, the processing and post-processing methods, as well as a proposed 
mechanism for the formation of droplets created in this manner, are discussed in detail.  
Furthermore, the role of different stabilizers in the formation/stabilization of the 
engineered particulates and any effect their structure or concentration may have on the 
generated particles is assessed. Materials and Methods 
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Materials 
We utilized a customized stainless steel pressure vessel was fabricated in house to 
have a sight glass, pressure gauge and a cooling coil sampling port.  Carvedilol was 
purchased from TCI America (Portland, OR).  And we purchased Poloxamer 407, 
Sodium Carboxymethyl Cellulose and Tween 80 from Spectrum Chemicals (Gardena, 
CA, USA). 
 
Methods 
 
Processing Parameters for the Production of Carvedilol Particles 
Samples were all heated from 40 – 125 oC under stirring at 200 rpm with a 
maximal pressure of between 20-25 psi.  Samples where then allowed to continue stirring 
for 5 minutes at 125 oC /20 psi, then removed from heat and allowed to cool for 30 
minutes. (See Figure 6.1  for a detailed discussion description processing technique.) 
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Figure 6.1.  SHAPE Processing Overview and Schematic:  (1) A coarse, poly-disperse suspension of a poorly water-soluble 
drug (2) Increasing the temperature under pressure, to a point above the melting point of the drug (3) Upon 
further heating, the viscosity of the drug decreases to a point where a molten drug emulsion forms (4) With 
continued mixing, the droplet size is reduced to form a uniform emulsion, with dramatically reduced droplet size 
(5) The emulsion is then allowed to cool back to below the melting point of the drug to form mono-disperse 
crystals  
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Table 6-1.  Table of Formulations Screened with SHAPE. 
 
 
 
 
 
 
 
 
Formulation API % Surfactant %(w/v)
CARV-DI Carvedilol 0.50 N/A N/A
CARV-PA Carvedilol 0.50 Poloxamer 407 0.50
CARV-PB Carvedilol 0.50 Poloxamer 407 0.10
CARV-PC Carvedilol 0.50 Poloxamer 407 0.05
CARV-NA Carvedilol 0.50 NaCMC 0.50
CARV-NB Carvedilol 0.50 NaCMC 0.10
CARV-NC Carvedilol 0.50 NaCMC 0.05
CARV-1-PC Carvedilol 1.00 Poloxamer 407 0.50
CARV-1-PD Carvedilol 1.00 Poloxamer 407 1.00
CARV-PC-NaOH Carvedilol 0.50 Poloxamer 407 0.50
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Method for Collection of Particles 
Upon cooling to room temperature, particles were centrifuged at 4,000 rpm with a 
Hettick Universal 320R benchtop centrifuge for between 30 and 60 minutes, or until 
supernatant was clear.  The pellet was collected and dried at 35 oC +/- 5 oC overnight. 
 
Characterization of Formulations: 
 
Optical Light Microscopy 
Freshly processed formulations were equilibrated to room temperature and 
aliquoted onto glass microscope slides and covered with a cover-slip for visualization.  
An upright Leica M205 FA Stereoscope was used for imaging of the suspended particles, 
and digital images were captured using the onboard software. 
 
Dynamic Light Scattering (DLS)  
The Dynamic Light Scattering technique was utilized to obtain particle size 
information with a Malvern Zetasizer ZS.  Samples were diluted ~100x with DI water 
prior to analysis.  The Z-average particle size and the polydispersity index (PI) were 
determined for each formulation using the cumulant fit statistical analysis incorporated 
into the Zetasizer ver. 7.11 software.  
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Differential Scanning Calorimetry (DSC) 
To determine the physical state and thermal properties of the particulates, 
differential scanning calorimetry was performed on a Texas Instruments DSC Q200 
equipped with an auto-sampler.  Dried powders were weighed on an analytical balance to 
be between 1-5 mg and placed in aluminum sealed pans.  The heating profile was set to 
equilibrate at room temperature and ramp from ~25 ºC to 140 ºC at a rate of 10 
ºC/minute.  
 
Powder X-Ray Diffraction (PXRD) 
Powder X-ray diffraction patterns were captured by using a Spider R-axis X-Ray 
diffractometer (Rigaku Co., Ltd., Tokyo, Japan). Small agglomerates of powder were 
attached to a mineral oil coated nylon wire sample holder and placed directly into the 
aligned X-Ray beam bath.  The measurement conditions were as follows: target, Cu Kα; 
filter, Ni: voltage, 40 kV; current, 40 mA; scanning speed, 1 º/sec, with an exposure time 
of 10 minutes.  Diffraction patterns were collected around a complete rotational axis. 
This pattern was then converted to 2 dimensional diffractograms and 2-theta angles were 
plotted against signal intensity in counts per second (Cps). 
 
Scanning Electron Microscopy- (SEM) 
Dry powder samples were fixed to SEM stubs using conductive double sided 
adhesive tape.  The samples were sputter coated with 15 nm of platinum/palladium using 
an ion sputter in a nitrogen atmosphere.  The morphological features as well as 
dimensional characteristics of the powders were visualized at multiple magnifications 
using SEM (Zeiss Supra 40V, Carl Zeiss Microscopy GmbH, Jena, Germany) 
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Figure 6.2.  Molecular Structure of Carvedilol with Physicochemical Properties. 
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RESULTS AND DISCUSSION 
 
Production of Engineered Particles 
 
Method of Production of Particles and Conditions/Formulation Rationale  
Our primary goal in investigating this new particle engineering technique was to 
determine the effect that different stabilizers have on the nature of the particles generated 
with this novel technique.  It is established that many different excipient stabilizers can 
play various roles in the production and preservation of nanostructured or micronized 
particulates (1) .  In this preliminary assessment, we chose two polymeric stabilizers with 
different potential mechanisms.  Sodium carboxymethyl cellulose (NaCMC) was selected 
for its potential to be adsorbed onto the surface of the newly formed particles and to 
possibly disrupt crystal growth or to serve as a protective to prevent agglomeration due to 
steric effects.  Secondly, we chose poloxamer 407 because it can also be adsorbed onto 
the surface of newly formed particles, but as an amphiphilic polymer it can serve as a 
surfactant to reduce the interfacial tension at the interface between the particles and the 
aqueous phase (2).  In addition, it could possibly assist in the emulsification of the molten 
API droplets.  
The main processing variables/conditions for producing nano/micro-sized 
particles using SHAPE, are temperature, mixing rate and time.  While these parameters 
are singularly simple, they can be independently altered to create a near infinite number 
of Time-Temperature-RPM Profiles for processing materials.  For these experiments, 
instead of altering processing conditions we opted to select a basic temperature-time-
mixing profile in order to assess the contributions that surfactants have on the process.  
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For this profile, the suspension was mixed at around 400 rpm, which can easily be 
achieved with a magnetic stir bar.  We chose a moderate heating rate that can be achieved 
using a stirring hot plate.  For the maximal processing temperature, we selected 125 oC, 
which is approximately 5 oC over the melting point of Carvedilol.  The temperature was 
held for 5 minutes after the visual confirmation that an emulsion had formed.  The 
mixture was then cooled it back down to room temperature over a 30 minute period under 
constant mixing. 
 
Method for Collection Particles: 
 
The method used to harvest the engineered particles can have a tremendous effect 
on the characteristics of the powders produced.  This post-processing step is crucial and 
very dependent on what the dosage form selection or application the API will be used for.  
In this study we selected a basic centrifugation method because the only concern was 
investigating the characteristics of the particulates produced by this engineering method.  
Due the differences in the particle size distributions produced by SHAPE, differing 
amounts of centrifugation may be required to pellet different solid materials.  It was 
noticed that for carvedilol, the majority of the samples produced herein were able to be 
pelleted in an under 1 hour at 4000 rpm.  
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Particle Size and Morphology 
 
Optical Light Microscopy 
 
In order to assess if the particle size was indeed reduced during the processing, we 
quickly added a few drops of the suspension to a microscope slide and captured images.  
Figure 6.3 shows the raw, unprocessed carvedilol suspended in a 0.05% poloxamer 407 
solution.  Crystals are present in variety of sizes and shapes and some are quite large, on 
the order of 50 μm (by length).  As can be seen in Figure 6.4 , the freshly processed 
material from SHAPE is drastically reduced in particle size and the particle geometry is 
much more homogeneous.   
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Figure 6.3.  Light Microscope Image of Raw Unprocessed Carvedilol Suspended in 
0.05% poloxamer 407 solution. 
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Figure 6.4.  Light Microscope Image of SHAPE Processed Carvedilol (w/0.05% 
poloxamer 407)- Taken immediately after processing.  
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Dynamic Light Scattering (DLS) 
Upon equilibrating freshly prepared suspensions to room temperature, the particle 
size distributions were assessed using DLS.  DLS is additionally useful for determining 
the short range physical stability of the formulations.  Freshly engineered particles will be 
cooling from a molten state; therefore they are more susceptible to increased coalescence 
and ‘droplet’ aggregation, making monitoring their short-term stability essential.  As can 
be seen in Table 6-2, the Z-avg particle size for each of the formulations was in the 
micron range, demonstrating that the total particle size distribution (PSD) of the raw 
material can be reduced.  However, some of the formulations exhibited a large 
poydispersity index (PI).  This is an indicator of either particle aggregation or 
precipitation.  Furthermore, a clear difference can be seen between that of the suspension 
produced with poloxamer 407 vs that of NaCMC.  The particles produced from NaCMC 
were all larger and had broader size distributions.  The two formulations with the lowest 
particle size were both with 0.05% poloxamer 407.  Both of these produced particles with 
a Z-avg of less than one micron with a narrow PI.  As can be seen in the PSD 
distributions, the PC formulations displayed a smaller PI, and can thus be considered 
more homogeneous or uniform (example distribution in Figure 6.5).  Based off of this 
data, the PC formulations appear to the most optimal candidate.  They resulted in very 
small uniform particles that remained in stable suspension over the 30 minute cooling 
period.  This short range stability is important because it allows for a more broad range of 
post processing techniques.  The other formulations appear to either coalesce during the 
cooling phase or they are forming agglomerates upon equilibration, based off of the 
larger sizes and very high PI.  Future studies will be conducted to assess different post 
processing techniques and to further analyze the short term stability of these engineered 
particles.  
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Figure 6.5.  Example Dynamic Light Scattering Particle Size Distribution for SHAPE 
Processed Carvedilol. Formulation: 0.5% Carvedilol - 0.05% poloxamer 407 
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Table 6-2.  Dynamic Light Scattering Particle Size Data and Qualitative Description of 
SHAPE Processed Carvedilol Formulations. 
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Scanning Electron Microscopy 
Scanning electron microscopy was utilized for few different purposes in this 
investigation.  Most importantly, because we were analyzing and comparing carvedilol 
raw material to that of the processed material, it was expected for there to be a dramatic 
difference in their physicochemical properties and for this reason several different 
methods were used for comparison.  The bulk, raw material shown in Figure 6.6, is 
characterized by large, crystalline particles, with sharp edges.  The particles appear to be 
in a broad range of sizes, up to 100 µm, and all appear to be of the same particle 
morphology.  Then, when comparing the raw material to the SHAPE processed material 
Figure 6.7, at the same magnification, it can easily be seen that the SHAPE material has 
formed much larger particle agglomerates with irregular geometry.  In the SHAPE 
sample, these large agglomerates have a show a very rough surface.  Upon increasing the 
magnification in Figure 6.8, discrete individual platelet-type, disk particles can be 
visualized.  These individual particles are relatively uniform and look as if they are 
packed tightly to form the larger secondary particles (i.e. agglomerates).  This is almost 
certainly due to the post-processing centrifugation step, as the suspension was spun down 
into a pellet for drying and collection.  Based off these SEM images, the particles appear 
to be about 2 or 3 microns in diameter, but because they are disk like particles and are 
laying flat it is difficult to assess their thickness.  These images confirm the micronization 
process was successful and support the findings from light microscopy.  The DLS sizing 
indicated that these particles were submicron; however, DLS measurements require a few 
assumptions based off of particle geometry, and because these particles were found to be 
plate-like, the reduced reliability of the DLS data must be considered. 
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Figure 6.6.  Scanning Electron Micrograph of Raw Unprocessed Carvedilol. 
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Figure 6.7.  Scanning Electron Micrograph of SHAPE Processed Carvedilol 
Microparticle Agglomerates.  (Formulation, CARV-PC: 0.5% Carvedilol- 
0.05% poloxamer 407) 
 
 
 
 
 
 196
 
 
 
 
 
 
Figure 6.8.  Scanning Electron Micrograph of SHAPE Processed Carvedilol 
Microparticles Under Higher Magnification.(Formulation, CARV-PC: 0.5% 
Carvedilol- 0.05% poloxamer 407) 
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Physicochemical Properties of SHAPE Processed Carvedilol 
 
Crystalline Characteristics 
 
The PXRD diffraction patterns for raw, unprocessed carvedilol were compared to 
that of the SHAPE processed material.  The raw carvedilol has several major distinct 
diffraction peaks appearing at 2-theta angles of: 5.8 ,11.6 & 14.8.  These peaks confirm 
that the starting material is the Polymorphic Form II.  Several groups have extensively 
studied this polymorph and it is well-characterized (3).  Upon processing carvedilol with 
SHAPE, the PXRD patterns reflect a definite change in the crystal morphology. Each 
batch of processed carvedilol exhibited a near identical diffraction pattern. Most 
noticeable the disappearance of the 2-theta peak at 5.8 and the emergence of 2-theta peak 
at ~8.3.  The main peaks that appear in these diffractograms are highly similar to that of 
the Form III polymorph with having nearly all of the same main peaks.  However, in 
order to be certain of this categorization, further analysis would need to be conducted.  
Furthermore, while comparing the peaks between the processed and unprocessed 
materials, it is noticeable that the peak intensities of the processed material are smaller 
than that of the raw material.  This decrease in signal intensity is most likely attributed to 
the dramatic reduction in particle size and/or increased noise due to a relative increase 
mounting adhesive. 
 
 
 
 
 
 198
 
 
 
 
Figure 6.9.  PXRD Diffractograms of Raw and Processed Carvedilol. A) Neat Carvedilol 
before Processing. B) Neat Carvedilol Processed with only Deionized 
Water. C) 0.5% CARV- 0.5% Poloxamer 407. D) 0.5% CARV- 0.05% 
Poloxamer 407. E) 1% CARV- 0.05% Poloxamer 407 
 
 
 
 
 
 199
Physicochemical Properties of SHAPE Processed Carvedilol 
Crystalline Characteristics 
The PXRD diffraction patterns for raw, unprocessed carvedilol were compared to 
that of the SHAPE processed material.  The raw carvedilol has several major distinct 
diffraction peaks appearing at 2-theta angles of: 5.8 ,11.6 & 14.8.  These peaks confirm 
that the starting material is the Polymorphic Form II.  Several groups have extensively 
studied this polymorph and it is well-characterized (3).  Upon processing carvedilol with 
SHAPE, the PXRD patterns reflect a definite change in the crystal morphology.  Each 
batch of processed carvedilol exhibited a near identical diffraction pattern.  Most 
noticeable is the disappearance of the 2-theta peak at 5.8 and the emergence of 2-theta 
peak at ~8.3.  The main peaks that appear in these diffractograms are highly similar to 
that of the Form III polymorph with having nearly all of the same main peaks.  However, 
in order to be certain of this categorization, further analysis would need to be conducted.  
Furthermore, while comparing the peaks between the processed and unprocessed 
materials, it is noticeable that the peak intensities of the processed material are smaller 
than that of the raw material.  This decrease in signal intensity is most likely attributed to 
the dramatic reduction in particle size and/or increased noise due to a relative increase 
mounting adhesive but could also indicate the presence of some amorphous content. 
 
Thermal Behavior 
 
When investigating the possible occurrence of different polymorphic crystal 
forms it is important to assess the thermal behavior of the materials.  We noticed a 
marked difference in the thermal behavior between that of the raw and processed 
materials.  Most notable was the reduction in melting point of carvedilol in the processed 
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material Figure 6.10.  The melting point of raw CARV Form II was found to be approx 
114 oC, which is in agreement with literature values (3).  While the processed materials 
showed a roughly 20 oC drop in melting point.  This drop in melting point is attributed to 
the presence of a low melting point polymeric surfactant (poloxamer 407), however the 
possibility of eutectic formation cannot be ruled out.  But because the physical mixture of 
carvedilol and poloxamer material showed the same drop in melting point, this drop in 
melting point it is most likely due to the poloxamer melting and beginning to dissolve the 
carvedilol within the sample pan.  Furthermore, it should also be noted that the melting 
endotherms for the processed particles show more broadening compared to the neat 
carvedilol endotherm.  This broadening and melting point suppression could be attributed 
to the Kelvin effect described in the Gibbs-Thomson equation, as these particles have a 
different surface geometry and are much smaller than the raw material, as well as a 
portion of the material is sub-micron (4, 5).  In addition, the broadening and melting point 
suppression suggests that there is residual poloxamer remaining in the processed powder 
blend.  This can be explained by the nature of the particle collection technique and the 
experimental setup.  In order to collect the particles, they were centrifuged and dried from 
the surfactant solution; it is likely that an unavoidable film of poloxamer was retained in 
the powder upon drying.  Previously, others have described this occurrence with other 
surfactants that interact with a nanocrystal surface (6).  With these considerations the 
findings from the DSC thermograms support the findings from the PXRD data that 
indicates the formation of a possible different crystal form.  In addition, the presence of 
clear endotherms confirms that the particles undergo recrystallization and exist in 
crystalline form as a dry powder.  Further experimentation will be needed to provide 
more details about the nature and kinetics of the recrystallization process. 
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Figure 6.10.  DSC Thermograms of Raw Materials and Engineered Powders.  A) 1% 
Carvedilol- 0.05% Poloxamer 407. B) Carvedilol and Poloxamer 407 
Physical Mixture. C) Neat Poloxamer 407. D) Neat Carvedilol 
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CONCLUSIONS 
 
In this investigation we determined that SHAPE is a viable method for the 
production of fine particles with altered morphology and physicochemical characteristics. 
It was also concluded that the selection of surfactant/stabilizer can have a tremendous 
effect on the characteristics of the particles generated.  Poloxamer 407 was found to be a 
superior stabilizer compared to NaCMC, at both aiding the reduction of particle size and 
the prevention of agglomeration of newly formed particulates.  Finally, while the 
technique was successful at reducing particle size and altering particle morphology, much 
more research needs to be conducted in order to further optimize the processing 
parameters to engineer specific particles for different applications and to gain further 
understanding of some of the underlying mechanisms in this complex dynamic system.  
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Chapter 7 :  Concluding Remarks 
 
DISSERTATION CONCLUSION 
 
Studies utilizing aerosol loaded toroidal vortices for ocular drug have shown their 
ability to deliver precise small volumes of liquid in a tunable and reproducible manner.  
The use of this technology enables characteristics that are not currently attainable with 
existing technologies.  Some of these features include: the ability to readily control the 
geometric dimensions of the emitted aerosol plume, enhanced control and tunability of 
the emitted aerosol characteristics, and the ability to finely tune the velocity of the 
aerosol. 
Investigations comparing toroidal vortex velocity and deposition, showed that by 
controlling the translational velocity of toroidal vortex one could directly control the 
amount of drug that is deposited onto a surface.  Furthermore, by increasing the aerosol 
concentration or the concentration of the active ingredient in the nebulized solution the 
deposition efficiency can be directly increased, allowing for dosing over a wide range of 
therapeutic concentrations.  Other investigations revealed that use of an electronic 
solenoid actuator offers high degree of control of the aerosol velocity and these vortices 
can be emitted at a desired speed by adjusting the energy used to actuate the membrane.  
In addition, it was found that the forces generated by these impacting toroidal vortices are 
far below that of which is normally experienced with standard eye drop solutions, thus 
ensuring that administration will be comfortable and patient friendly.   
The research conducted and outlined here in this dissertation has demonstrated the 
feasibility of the use of aerosol loaded toroidal vortices for topical ocular drug 
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administration.  Furthermore, when combined with other formulation strategies, the use 
of this technology can be applied to a very wide range of therapeutic agents and 
potentially be useful in solving some of the many problems are faced in modern ocular 
drug delivery. 
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